Journal Articles 1987-2009
1. Abdallah, A. B., Scheier, L. M., Inciardi, J. A., Copeland, J., & Cottler, L. B. (2007). A psycho-economic model of ecstasy consumption and related consequences: A multi-site study with community samples. Substance Use and Misuse 42(11), 1651-1684.
2. Amato, L., Davoli, M., Perucci, C., Ferri, M., Faggiano, F., & Mattick, R.P. (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment 28, 321-329.
3. Anderson, R., Haas, M., & Shanahan, M. (2008). The cost-effectiveness of cervical screening in Australia: What is the impact of screening at different intervals or over a different age range? Australian and New Zealand Journal of Public Health 32(1), 43-52.
4. Andrews, G., Henderson, A.S., & Hall, W. (2001). Prevalence, comorbidity, disability and service utilisation: An overview of the Australian National Mental Health Survey. British Journal of Psychiatry 178, 145-153.
5. Anthony, J.C. & Degenhardt, L. (2007). Projecting the impact of changes in cannabis use upon schizophrenia in England and Wales: The role of assumptions and balance in framing an evidence-based cannabis policy. Addiction 102, 515-516.
6. Baillie, A. J. & Mattick, R.P. (1996). Benzodiazepine dependence questionnaire: Development, reliability and validity. British Journal of Psychiatry 169, 276-281.
7. Baillie, A. J., Mattick, R.P., & Hall, W. (1994). Self-quitting smoking: Estimation of an unaided abstinence rate by meta-analysis. Australian Journal of Public Health 19, 29-31.
8. Baillie, A. J., Mattick, R.P., Hall, W., & Webster, P. (1994). Meta-analytic review of smoking cessation interventions. Drug and Alcohol Review 13, 157-170.
9. Baillie, A., Mattick, R. P., Webster, P., & Chen, R. (1993). People receiving treatment for drug and alcohol problems in Australia. NIDA Research Monograph Series (132), 44.
10. Baillie, A., Webster, P., & Mattick, R.P. (1992). An Australian survey of the procedures used for the treatment of opiate users. Drug and Alcohol Review 11, 343-354.
11. Baker, A., Heather, N., Wodak, A., Dixon, J., & Holt, P. (1993). Evaluation of a cognitive-behavioural intervention for HIV prevention among injecting drug users. AIDS 7, 247-256.
12. Baker, A., Kochan, N., Dixon, J., Wodak, A., & Heather, N. (1994). Drug use and HIV risk-taking behaviour among injecting drug users not currently in treatment in Sydney, Australia. Drug and Alcohol Dependence 34(2), 155-160.
13. Baldwin, S., Lawson, A., Mooney, J., Braggins, F., Carnegie, E., McLean, G., Robertson, I., & Heather, N. (1991). Effectiveness of pre-release alcohol education courses for young offenders in a penal institution. Behavioural Psychotherapy 19, 321-331.
14. Baldwin, S., Lawson, A., Mooney, J., Braggins, F., Carnegie, E., McLean, G., Robertson, I., & Heather, N. (1991). Comparison of effectiveness of behavioural and talk-based alcohol education courses. Behavioural Psychotherapy 19, 157-172.
15. Bammer, G., Ritter, A., Kutin, J. J., & Lintzeris, N. (2009). Fast-tracking implementation through trial design: the case of buprenorphine treatment in Victoria. Australian and New Zealand Journal of Public Health 33(1), 34-39.
16. Barber, J.G., Cooper, B.K., & Heather, N. (1991). The Situational Confidence Questionare (heroin). International Journal of Addictions 26, 565-575.
17. Bell, J. (1991). Pain and addiction. Drug and Alcohol Review 10, 247-252.
18. Bell, J. (1992). Treatment dependence. Preliminary description of yet another syndrome. British Journal of Addiction 87, 1049-1054.
19. Bell, J. (1997). Australian trends in opioid prescribing for chronic, non-cancer pain, 1986-1996. Medical Journal of Australia 167, 26-29.
20. Bell, J. (1998). Self report among injecting drug users. Drug and Alcohol Dependence 51, 267-268.
21. Bell, J. (2008). Speciality recognition of addiction medicine in Australia. Addiction 103(5), 701-702.
22. Bell, J. & Batey, W. (1992). Medicine and the addictions (Editorial). Australian and New Zealand Journal of Medicine 22, 202-203.
23. Bell, J., Burrell, T., Indig, D., & Gilmour, S. (2005). Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. Drug and Alcohol Dependence 81, 55-61. (abstract available)
24. Bell, J., Byron, G., Gibson, A., & Morris, A. (2004). A pilot study of buprenorphine-naloxone combination tablet (Suboxone®) in treatment of opioid dependence. Drug and Alcohol Review 23, 311-317.
25. Bell, J., DiGuisto, E., & Byth, K. (1992). Who should receive methadone maintenance? British Journal of Addiction 87, 527-532.
26. Bell, J., Hall, W., & Byth, K. (1992). Changes in criminal activity after entering methadone maintenance. British Journal of Addiction 87, 251-258.
27. Bell, J., Mattick, R., Chan, J., Hay, A., & Hall, W. (1997). Methadone maintenance and drug-related crime. Journal of Substance Abuse 9, 15-25.
28. Bell, J. R., Ryan, A., Mutch, C., Batey, R., & Rea, F. (2008). Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: Follow-up of a randomised trial. Drug and Alcohol Dependence 96(1-2), 183-186.
29. Bell, J., Shanahan, M., Mutch, C., Rea, F., Ryan, A., Batey, R., Dunlop, A., & Winstock, A. (2007). A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 102, 1899-1907.
30. Bell, J., Trinh, L., Butler, B., Randall, D., & Rubin, G. (2009). Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 104(7), 1193-1200.
31. Bell, J., Young, M.R., Masterman, S., Morris, A., Mattick, R.P., & Bammer, G. (1999). A pilot study of naltrexone-accelerated detoxification in opioid dependence. Medical Journal of Australia 171, 26- 30.
32. Bellis, M. A., Hughes, K. E., Dillon, P., Copeland, J., & Gates, P. (2007). Effects of backpacking holidays in Australia on alcohol, tobacco and drug use of UK residents. Bmc Public Health 7.
33. Ben Abdallah, A., Scheier, L.M., Inciardi, J.A., Copeland, J. & Cottler, L.B. (2007). A psycho-economic model of ecstasy consumption and related consequences: A multi-site study with community samples. Substance Use and Misuse 42, 1651-1684.
34. Black, E. & Degenhardt, L. (2006). Drug-related aggression among injecting drug users. NSW Public Health Bulletin 17, 12.
35. Bonevski, B., Doran, C., Bailey, C., & Lowe, J. (2002). Description of an early discharge post-acute care program: Length of hospital stay, patient and carer needs and cost. Australian Health Review 25, 78-86.
36. Bonomo, Y., Coffey, C., Wolfe, R., Lynskey, M., Bowes, G., & Patton, G. (2001). Alcohol-related problem behaviours in 16-17 year old Australian students. Addiction 96, 1485-1496.
37. Boot, B., Hall, W., & Andrews, G. (1997). Disability, outcome and casemix in acute psychiatric in-patient units. British Journal of Psychiatry 171, 242-246.
38. Boot, B., McGregor, I.S., & Hall, W. (2000). MDMA (Ecstasy) neurotoxicity: Assessing and communicating the risks. Lancet 355, 1818-1821.
39. Brady, M., Dawe, S., & Richmond, R. (1998). Expanding knowledge among Aboriginal service providers on treatment options for excessive alcohol use. Drug and Alcohol Review 17, 69-76.
40. Bramley-Moore, S.R., Wodak, A.D., Day, R.O., & Lachlan, R.L. (1998). Patterns of analgesic prescribing patients with chronic non-malignant pain in NSW. The Australian Journal of Hospital Pharmacy 28, 83-88.
41. Breen, C., Degenhardt, L., Bruno, R., Roxburgh, A., & Jenkinson, R. (2004). The effects of restricting publicly subsidised temazepam capsules on benzodiazepine use among injecting drug users in Australia. Medical Journal of Australia 181, 300-304.
42. Breen, C., Degenhardt, L., Kinner, S., Bruno, R., Jenkinson, R., Matthews, A., & Newman, J. (2006). Alcohol use and risk taking among regular ecstasy users. Substance Use and Misuse 41, 1095-1109.
43. Breen, C., Harris, S., Lintzeris, N., Mattick, R.P., Hawken, L., Bell, J., Ritter, A.J., Lenné, M., & Mendoza, E. (2003). Cessation of methadone maintenance treatment using buprenorphine: Transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug and Alcohol Dependence 71, 49-55. (abstract available)
44. Breen, C., Roxburgh, A. & Degenhardt, L. (2005). Gender differences among regular injecting drug users in Sydney, Australia, 1996-2003. Drug and Alcohol Review 24, 353-358.
45. Buck, D.J., Richmond, R.L., & Mendelsohn, C.P. (2000). Cost-effectiveness analysis of a family physician delivered smoking cessation program. Preventive Medicine 31, 641-648.
46. Buhrich, N., Hodder, T., & Teesson, M. (2000). Prevalence of cognitive impairment among homeless people in inner Sydney. Psychiatric Services 51, 520-521. (abstract available)
47. Buhrich, N., Hodder, T., & Teesson, M. (2000). Lifetime prevalence of trauma among homeless people in Sydney. Australian and New Zealand Journal of Psychiatry 34, 963-966.
48. Buhrich, N., Hodder, T. & Teesson, M. (2003). Schizophrenia among homeless people in inner-Sydney: Current prevalence and historical trends. Journal of Mental Health 12, 51-57. (abstract available)
49. Burns, L. & Mattick, R.P. (2007). Using population data to examine the prevalence and correlates of neonatal abstinence syndrome. Drug and Alcohol Review 26, 487-492.
50. Burns, L., Mattick, R.P. & Cooke, M. (2006). The use of record linkage to examine illicit drug use in pregnancy. Addiction 101, 873-882.
51. Burns L., Mattick, R.P. & Cooke, M. (2006). The use of linked data to examine alcohol use in pregnancy. Alcoholism: Clinical and Experimental Research 30, 642-648.
52. Burns, L., Mattick, R.P., Lim, K., Wallace, C. (2007). Methadone in pregnancy: Treatment retention and neonatal outcomes. Addiction 102, 264-270.
53. Burns, L., Mattick, R. P., & Wallace, C. (2008). Smoking patterns and outcomes in a population of pregnant women with other substance use disorders. Nicotine & Tobacco Research 10(6), 969-974.
54. Burns, L. & Teesson, M. (2002). Alcohol use disorders comorbid with anxiety, depression and drug use disorders: Findings from the Australian National Survey of Mental Health and Well-Being. Drug and Alcohol Dependence 68, 299-308.
55. Burns, L., Teesson, M., & O'Neill, K. (2005). The impact of comorbid anxiety and depression on alcohol treatment outcomes. Addiction, 100(6), 787-796.
56. Butler, T., Dolan, K., Ferson, M., McGuiness, L., Brown, P., & Robertson, P. (1997). Hepatitis B and C in New South Wales prisons. Prevalence and risk factors. Medical Journal of Australia 166, 127-130.
57. Butler, T., Levy, M., Dolan, K., & Kaldor, J. (2003). Drug use and its correlates in an Australian Prisoner Population. Addiction Research and Theory 11, 89-101.(abstract available)
58. Byrne, A. & Dolan, K. (1998). Methadone treatment is widely accepted in prisons in New South Wales (letter to the editor). British Medical Journal 316, 1744.
59. Cadman, M. & Bell, J. (1998). Doctors detected self-administering opioids in New South Wales, 1985-1994: Characteristics and outcomes. Medical Journal of Australia 169, 419-421.
60. Campbell, I., & Chalmers, J. (2008). Job quality and part-time work in the retail industry: An Australian case study. International Journal of Human Resource Management, 19(3), 487-500.
61. Carey, D.L., Day, R.O., Cairns, D.R., Pearce, G.A., Wodak, A.D., & Lauchlan, R.L. (1992). An attempt to influence hypnotic and sedative drug usage. Medical Journal of Australia 156, 389-393.
62. Caulkins, J. P., Dietze, P., & Ritter, A. (2007). Dynamic compartmental model of trends in Australian drug use. Health Care Management Science, 10(2), 151-162.
63. Chambers, G., Grayson, N., Shanahan, M., Chapman, M., & Sullivan, E. (2007). The inpatient birth-admission costs of singleton and multiple births after ART treatment - A comparison with spontaneously conceived births. Australian & New Zealand Journal of Obstetrics & Gynaecology, 47, A3-A4.
64. Chambers, G. M., Chapman, M. G., Grayson, N., Shanahan, M., & Sullivan, E. A. (2007). Babies born after ART treatment cost more than non-ART babies: A cost analysis of inpatient birth-admission costs of singleton and multiple gestation pregnancies. Human Reproduction, 22(12), 3108-3115.
65. Chan, J.S.K., Kuk, A.Y.C., & Bell, J. (1997). A likelihood approach to analysing longitudinal bivariate binary data. Biometrical Journal 39, 409-421.
66. Chan, J.S.K., Kuk, A.Y.C., Bell, J., & McGilchrist, C. (1998). The analysis of methadone clinic data using marginal and conditional logistic models with mixture or random effects. The Australian and New Zealand Journal of Statistics 40, 1-10.
67. Charlson, F., Degenhardt L., McLaren J., Hall, W., & Lynskey, M. (2009). A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiology and Drug Safety 18(2), 93-103.
68. Chesher, G., & Wodak, A. (1990). Evolving a new policy for illicit drugs. Journal of Drugs Issues 20, 555-561.
69. Chesher, G. & Greeley, J. (1992). Tolerance to the effects of alcohol. Alcohol, Drugs and Driving 8, 93-106.
70. Coffey, C., Carlin, J.B., Lynskey, M.L., Degenhardt, L., & Patton, G.C. (2003). Cannabis dependence in young adults: Findings from the Victorian Adolescent Health Cohort Study. Journal Salud Ciencia.
71. Coffey, C., Carlin, J.B., Degenhardt, L., Lynskey, M., Sanci, L., & Patton, G.C. (2002). Cannabis dependence in young adults: An Australian population study. Addiction 97, 187-194.(abstract available)
72. Coffey, C., Lynskey, M., Wolfe, R., & Patton, G.C. (2000). Initiation and progression of cannabis use in a population-based Australian adolescent longitudinal study. Addiction 95, 1679-1690.
73. Conigrave, K.M., Degenhardt, L.J., Whitfield, J.B., Saunders, J.B., Helander, A., & Tabakoff, B. (2002). CDT, GGT, and AST as markers of alcohol use:The WHO/ISBRA Collaborative Project. Alcoholism: Clinical and Experimental Research 26, 332-339.
74. Conigrave, K., Hall, W. & Saunders, J. B. (1995). The AUDIT questionnaire: Choosing a cut-off score. Addiction 90, 1349-1356.
75. Conroy, E., Degenhardt, L. & Day, C. (2007). Impact of drug market changes on substance-using pregnant women in three key Sydney drug markets. Women and Health 44, 93-105.
76. Conroy, E., Degenhardt, L., Mattick, R. P., & Nelson, E., C. (2009). Child maltreatment as a risk factor for opioid dependence: Comparison of family characteristics and type and severity of child maltreatment with a matched control group. Child Abuse & Neglect 33(6), 343-352.
77. Conroy, E., Kimber, J., Dolan, K., & Day, C. (2008). An examination of the quality of life among rural and outer metropolitan injecting drug users in NSW, Australia. Addiction Research & Theory, 16(6), 607-617.
78. Cooke, M., Mattick, R.P., & Barclay, L. (1996). Predictors of brief smoking intervention in a midwifery setting. Addiction 91, 1715-1725.
79. Cooke, M., Mattick, R.P., & Campbell, E. (1998). The influence of individual and organizational factors on the reported factors on the reported smoking intervention practices of staff in 20 antenatal clinics. Drug and Alcohol Review 17, 175-185.
80. Cooke, M., Mattick, R.P., & Campbell, E. (1999). The dissemination of a smoking cessation program to 23 antenatal clinics: The predictors of program adoption by managers. Australian & New Zealand Journal of Public Health 23, 99-103.
81. Cooke, M., Mattick, R.P., & Campbell, E. (2000). A description of the adoption of the 'Fresh Start' smoking cessation programme by antenatal clinic managers. Australian Journal of Advanced Nursing 18, 13-21.
82. Cooke, M., Mattick, R.P., & Walsh, R.A. (2001). Differential uptake of a smoking cessation programme disseminated to doctors and midwives in antenatal clinics. Addiction 96, 495-506.(abstract available)
83. Cooke, M., Mattick, R.P., Walsh, R. (2001). Implementation of the ‘fresh start’ smoking cessation program in 23 antenatal clinics: A randomized controlled trial investigating two methods of dissemination. Drug and Alcohol Review 20, 19-28.
84. Copeland, J. (1992). "She who pays the piper calls the tune": A response (letter to the editor). Drug and Alcohol Review 11, 401-402.
85. Copeland, J. (1993). Feminism and Addiction (book review). Drug and Alcohol Review 12, 117-118.
86. Copeland, J. (1995). Alcohol, Gender and Culture (book review). Addiction 90, 444-445.
87. Copeland, J. (1995). Women and Substance Use (book review). Drug and Alcohol Review 14, 245.
88. Copeland, J. (1995). Addictive Behaviors in Women (book review). Drug and Alcohol Review 14, 338.
89. Copeland, J. (1995). Maturing Out: An Empirical Study of Personal Histories and Processes in Hard-drug Addiction (book review). Drug and Alcohol Review 14, 340-341.
90. Copeland, J. (1997). A qualitative study of the perceptions of treatment services and 12-step programs among women who self-managed change in addictive behaviours. Journal of Substance Abuse Treatment 13, 1-8.
91. Copeland, J. (1998). Gender and Addictions: Men and Women in Treatment (book review). Addiction 93, 1599-1600.
92. Copeland, J. (1998). A qualitative study of self-managed change in substance dependence among women. Contemporary Drug Problems 25, 321-345.
93. Copeland, J. (1999). Women and drink driving (letter). Drug and Alcohol Review 18, 113.
94. Copeland, J. (2001). Mothers and illicit drugs: Transcending the myths (book review). Addiction 96, 783.
95. Copeland, J. (2001). Women’s Perspectives on Drugs and Alcohol: The Vicious Circle (book review). Addiction 96, 1681-1685.
96. Copeland, J. (2001). Nursing interventions for cannabis use disorder: Part 1 Prevalence and harms. Pulse: Information Sheet of the Royal College of Nursing Australia, 1-2.
97. Copeland, J. (2001). Nursing interventions for cannabis use disorder: Part 2 Prevalence and harms. Pulse: Information Sheet of the Royal College of Nursing Australia, 1-2.
98. Copeland, J. (2002). Dealing: Women in the Drug Economy (book review). Australian and New Zealand Journal of Public Health 26, 292.
99. Copeland, J. (2002). Drug Misuse and Motherhood (book review). Addiction 97, 1228.
100. Copeland, J. (2003). The Handbook of Addiction Treatment for Women (book review). Drug and Alcohol Review 22, 96-97.
101. Copeland, J. (2004). Developments in the treatment of cannabis use disorder. Current Opinion in Psychiatry 17, 161-167.
102. Copeland, J. (2005). Addiction and Life Course (book review). Addiction 100, 1032-1033.
103. Copeland, J. (2005). Cannabis problems and their management. Drugs and Alcohol Today 5, 20-25.
104. Copeland, J. (2006). Management of cannabis use disorder. Directions in Addiction Treatment & Prevention 10, 15-24.
105. Copeland, J. & Conroy, A. (2001). Australian National Minimum Data Set for Clients of Alcohol and Other Drug Treatment Services: Findings of the national pilot and developments in implementation. Drug and Alcohol Review 20, 295-298.
106. Copeland, J. & Dillon, P. (2005). The health and psycho-social consequences of ketamine use. International Journal of Drug Policy 16, 122-131.
107. Copeland , J., Dillon, P. & Gascoigne, M. (2006). Ecstasy and the concomitant use of pharmaceuticals. Addictive Behaviors 31, 367-370.
108. Copeland, J. & Hall, W. (1992). A comparison of predictors of treatment drop-out of women seeking drug and alcohol treatment in a specialists women’s and two traditional mixed-sex treatment services. British Journal of Addiction 87, 1293-1302.
109. Copeland, J. & Hall, W. (1992). A comparison of women seeking drug and alcohol treatment in a specialist women’s & two traditional mixed-sex treatment services. British Journal of Addiction 87, 1293-1302.
110. Copeland, J., Hall, W., Didcott, P.,& Biggs, V. (1993). A comparison of a specialist women’s alcohol and other drug treatment service with two traditional mixed-sex services: Client characteristics and treatment outcome. Drug and Alcohol Dependence 32, 81-92.
111. Copeland, J., Howard, J., & Fleischmann, S. (1998). Gender, HIV knowledge and risk-taking behaviour among substance using adolescents in custody in New South Wales. Journal of Substance Misuse 3, 206-212.
112. Copeland, J., Howard, J., Keogh, T., & Seidler, K. (2003). Patterns and correlates of substance use amongst juvenile detainees in New South Wales 1989-1999. Drug and Alcohol Review 22, 15-20.(abstract available)
113. Copeland, J., Howard, J., Keogh, T., & Seidler, K. (2003). Drugs and blood-borne viruses: Knowledge and risk-taking behaviour among detained adolescents in New South Wales. International Journal of Forensic Psychology 1, 85-91.
114. Copeland, J. & Indig, D. (2004). Patterns and correlates of treatment: Findings of the 2000-2001 NSW minimum dataset of clients of alcohol and other drug treatment services. Drug and Alcohol Review 23, 185-194.
115. Copeland, J. & Martin, G. (2004). Web-based interventions for substance use disorders: A qualitative review. Journal of Substance Abuse Treatment 26, 109-116.(abstract available)
116. Copeland, J. & Maxwell, J.C. (2007). Correlates and outcomes of cannabis treatment among legally coerced versus non-coerced adults in Texas. BMC Public Health 7:111.
117. Copeland, J., Peters, R., & Dillon, P. (1998). Anabolic-androgenic steroid dependence in a woman (correspondence). Australian and New Zealand Journal of Psychiatry 32, 589.
118. Copeland, J., Peters, R., & Dillon, P. (1998). A study of 100 anabolic-androgenic steroid users (letter to the editor). Medical Journal of Australia 168, 311.
119. Copeland, J., Peters, R., & Dillon, P. (2000). Anabolic-androgenic steroid use disorders among a sample of Australian competitive and recreational users. Drug and Alcohol Dependence 60, 91-96.
120. Copeland, J. & Rankin, J. (1997). Maximising the opportunity for a minimum data set (Editorial). Drug and Alcohol Review 16, 205-206.
121. Copeland, J., Rees, V. & Swift, W. (1999). Health concerns and help-seeking among a sample entering treatment for cannabis dependence (correspondence). Australian Family Physician 28, 540-541.
122. Copeland, J., Stevenson, R.J., Gates, P., & Dillon, P. (2007). Young Australians and alcohol: The acceptability of ready-to-drink (RTD) alcoholic beverages among 12-30 year olds. Addiction 102, 1740-1746.
123. Copeland, J., & Swift, W. (2009). Cannabis use disorder: Epidemiology and management. International Review of Psychiatry 21(2), 96-103.
124. Copeland, J., Swift, W., Howard, J., Roffman, R.A., Stephens, R.S. & Berghuis, J. (2001). A randomised controlled trial of brief interventions for cannabis problems among young offenders. Drug and Alcohol Dependence 63, s32.(abstract available)
125. Copeland, J., Swift, W., & Rees, V. (2000). Brief interventions for cannabis dependence. DrugWise February, 51-52.
126. Copeland, J., Swift, W., & Rees, V. (2001). Clinical profile of participants in a brief intervention program for cannabis use disorder. Journal of Substance Abuse Treatment 20, 45-52.(abstract available)
127. Copeland, J., Swift, W. & Reid, A. (2004). Young cannabis users’ attitudes and beliefs about cannabis drug education. Journal of Drug Education and Awareness 1, 119-127.
128. Copeland, J., Swift, W., Roffman, R., & Stephens, R. (2001). A randomised controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. Journal of Substance Abuse Treatment 21, 55-64.(abstract available)
129. Crawford, J. & Heather, N. (1987). Public attitudes to the disease concept of alcoholism. International Journal of the Addictions 22, 1129-1138.
130. Crisp, B.R., Barber, J.G., Ross, M.W., Wodak, A., Gold, J., & Miller, M.E. (1993). Injecting drug users and HIV/AIDS: Risk behaviours and risk perception. Drug and Alcohol Dependence 33, 73-80.
131. Crofts, N., Jolley, D., Kaldor, J., van Beek, I., & Wodak, A. (1997). Epidemiology of hepatitis C virus infection among injecting drug users in Australia. Journal of Epidemiology and Community Health 51, 692-697.
132. Cruickshank, C. C., Montebello, M. E., Dyer, K. R., Quigley, A., Blaszczyk, J., Tomkins, S., et al. (2008). A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug and Alcohol Review, 27(3), 326-333.
133. Darke, S. (1991). A brief intervention to reduce risk-taking behaviour among injecting drug users. Newsletter of the International Working Group on AIDS and Drug Use 5 (May), 61.
134. Darke, S. (1991). AIDS. Sexual Behaviour and Intravenous Drug Use (book review). Drug and Alcohol Review 10, 287.
135. Darke, S. (1992). AIDS and Alcohol/Drug Abuse. Psychosocial Research (book review). Drug and Alcohol Review 11, 207.
136. Darke, S. (1992). Cocaine, AIDS, and Intravenous Drug Use (book review). British Journal of Addiction 87, 1604.
137. Darke, S. (1992). Injecting drug users and Human Immunodeficiency Virus: What do we know? Drug and Alcohol Review 11, 153-161.
138. Darke, S. (1992). The measurement of outcome in opiate treatment evaluation studies. Drug and Alcohol Review 11, 169-175.
139. Darke, S. (1994). The use of benzodiazepines among injecting drug users. Drug and Alcohol Review 13, 63-69.
140. Darke, S. (1994). Benzodiazepine use among injecting drug users: Problems and implications (Editorial). Addiction 89, 379-382.
141. Darke S. (1994). The prescribing of benzodiazepines to injecting drug users. A reply to Dr Seivewright (letter to the editor). Addiction 89, 1703.
142. Darke, S. (1995) Ne'er the twain. Comments on Dr McKeganey's Editorial (Invited commentary). Addiction 90, 761-762.
143. Darke, S. (1995). Methodological Issues in AIDS Behavioural Research (book review). Addiction 90, 993-994.
144. Darke, S. (1996). Psychotherapy, Psychological Treatments and the Addictions (book review). British Medical Journal 312, 1309.
145. Darke, S. (1997). Source Book of Substance Abuse and Treatment (book review). Addiction 92, 1037.
146. Darke, S. (1998). Self-report among injecting drug users: A review. Drug and Alcohol Dependence 51, 253-263.
147. Darke, S. (1998). Antisocial personality disorder, psychopathy and injecting heroin use. Drug and Alcohol Dependence 52, 63-69.
148. Darke, S. (1999). Heroin in the Age of Crack Cocaine (book review). Contemporary Psychology 44, 95-97.
149. Darke, S. (1999). Attacking overdose on the home front. Comments on Strang et al "Preventing opiate overdose fatalities with take-home naloxone: Prelaunch study of possible impact and acceptability". Addiction 94, 205.
150. Darke, S. (2001). The Impact of Harm Reduction Based Methadone Treatment on HIV Infection and Mortality (book review). Addiction 96, 1072.
151. Darke, S. (2002). UK Drugs Unlimited. New Research and Policy Lessons on Illicit Drug Use (book review). Addiction 97, 240-241.
152. Darke, S. (2003). Polydrug use and overdose: Overthrowing old myths. Addiction 98, 711.
153. Darke, S. (2004). Heroin supply and health: New perspectives (Editorial). Addiction 99, 275.
154. Darke, S. (2006). Preventing Harmful Substance Use: The Evidence for Policy and Practice (book review). Addiction 101, 902-903.
155. Darke, S. (2008). From the can to the coffin: Deaths among recently released prisoners. Addiction, 103, 256-257.
156. Darke, S. (2008). Truth is not always found in the laboratory. Addiction, 103(7), 1066-1067.
157. Darke, S. (2009). Substance use and violent death: a case for the 'too hard' basket? Addiction 104(7), 1063-1064.
158. Darke, S., Baker, A., Dixon, J., Wodak, A., & Heather, N. (1992). Drug use and HIV risk-taking behaviour among clients in methadone maintenance treatment. Drug and Alcohol Dependence 29, 263-268.
159. Darke, S., Cohen, J., Ross, J., Hando, J., & Hall, W. (1994). Transitions between routes of administration of regular amphetamine users. Addiction 89, 1077-1083.
160. Darke, S., & Duflou, J. (2008). Toxicology and circumstances of death of homicide victims in New South Wales, Australia 1996-2005. Journal of Forensic Sciences, 53(2), 447-451.
161. Darke, S., Duflou, J. & Kaye, S. (2007). Comparative toxicology of fatal heroin overdose cases and morphine positive homicide victims. Addiction 102, 1793-1797.
162. Darke, S., Duflou, J., & Torke, M. (2009). Toxicology and Circumstances of Completed Suicide by Means Other than Overdose. Journal of Forensic Sciences 54(2), 490-494.
163. Darke, S., Duflou, J., & Torke, M. (2009). Drugs and violent death: comparative toxicology of homicide and non-substance toxicity suicide victims. Addiction 104(6), 1000-1005.
164. Darke, S., Finlay-Jones, R., Kaye, S., & Blatt, T. (1996). Anti-social personality disorder and response to methadone maintenance treatment. Drug and Alcohol Review 15, 271-276.(abstract available)
165. Darke, S., Guinan, J., & Gold, J. (1991). The injecting and sexual behaviour of intravenous drug users. Medical Journal of Australia, 154(4), 294.
166. Darke, S. & Hall, W. (1990). The injecting and sexual behaviour of intravenous drug users (letter to the editor). Medical Journal of Australia 153, 43.
167. Darke, S. & Hall, W. (1995). Levels and correlates of polydrug use among heroin users and regular amphetamine users. Drug and Alcohol Dependence 39, 231-235.
168. Darke, S. & Hall, W. (1997). The distribution of naloxone to heroin users. Addiction 92, 1195-1199.
169. Darke, S. & Hall, W. (2003). Heroin overdose: Research and evidence-based intervention. Journal of Urban Health: Bulletin of the New York Academy of Medicine 80, 189-200.(abstract available)
170. Darke, S., Hall, W., & Carless, J. (1990). Drug use, injecting practices, and sexual behaviour of opioid users in Sydney, Australia. British Journal of Addiction 85, 1603-1609.
171. Darke, S., Hall, W., & Carless, J. (1990). The injecting and sexual behaviour of intravenous drug users in Sydney (letter to the editor). Medical Journal of Australia 152, 488.
172. Darke, S., Hall, W., Heather, N., Ward, J., & Wodak, A. (1991). The reliability and validity of a scale to measure HIV risk-taking among intravenous drug users. AIDS 5,181-185.
173. Darke, S., Hall, W., Heather, N., Wodak, A., & Ward, J. (1992). Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opioid users: The Opiate Treatment Index. British Journal of Addiction 87, 593-602.
174. Darke, S., Hall, W., Kaye, S., Ross, J., & Duflou, J. (2002). Hair morphine concentrations of fatal heroin overdose cases and living heroin users. Addiction 97, 977-984.(abstract available)
175. Darke, S., Hall, W., & Ross, M.W. (1992). Benzodiazepine prescribing and injecting drug users (letter to the editor). Medical Journal of Australia 157, 573-574.
176. Darke, S., Hall, W., Ross, M.W., & Wodak, A. (1992). Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. Drug and Alcohol Dependence 31, 31-36.
177. Darke, S., Hall, W., & Swift, W. (1994). Prevalence, symptoms and correlates of anti-social personality disorder among methadone maintenance clients. Drug and Alcohol Dependence 34, 253-257.
178. Darke, S., Hall, W., & Swift, W. (1994). Geographical differences in risk-taking among Sydney methadone maintenance patients: A comparison of inner city and outer south western methadone maintenance patients. Drug and Alcohol Review 13, 301-305.
179. Darke, S., Hall, W., Weatherburn, D. & Lind, B. (1999). Fluctuations in heroin purity and the incidence of fatal heroin overdose. Drug and Alcohol Dependence 54, 155-162.
180. Darke, S., Havard, A., Ross, J., Williamson, A., Mills, K., & Teesson, M. (2007). Changes in the use of medical services and prescription drugs among heroin users over two years. Drug and Alcohol Review 26, 153 – 159.
181. Darke, S., Heather, N., Hall, W., Ward, J., & Wodak, A. (1991). Estimating drug consumption in opioid users: Reliability and validity of a ‘recent use episodes’ method. British Journal of Addiction 86, 1311-1316.
182. Darke, S., Hetherington, K., Ross, J., Lynskey, M., & Teesson, M. (2004). Non-injecting routes of administration among entrants to three treatment modalities for heroin dependence. Drug and Alcohol Review 23, 177-183.
183. Darke, S. & Kaye, S. (2004). Attempted suicide among injecting and non-injecting cocaine users in Sydney, Australia. Journal of Urban Health 81, 505-515.
184. Darke, S., Kaye, S. & Duflou, J. (2005). Cocaine-related fatalities in New South Wales, Australia 1993-2002. Drug and Alcohol Dependence 77, 107-114.
185. Darke, S., Kaye, S. & Duflou, J. (2006). Systemic disease among cases of fatal opioids toxicity. Addiction 101, 1299-1305.
186. Darke, S., Kaye, S. & Duflou, J. (2006). Comparative cardiac pathology among deaths due to cocaine toxicity, opioids toxicity and non-drug-related causes. Addiction 101, 1771-1777.
187. Darke, S., Kaye, S., & Finlay-Jones, R. (1998). Drug use and injection risk-taking among prison methadone maintenance patients. Addiction 93, 1169-1175.
188. Darke, S., Kaye, S., & Finlay-Jones, R. (1998). Factor structure of psychopathy among methadone maintenance patients. Journal of Personality Disorders 12, 162-171.
189. Darke, S., Kaye, S., & Finlay-Jones, R. (1998). Antisocial personality disorder, psychopathy and injecting heroin use. Drug and Alcohol Dependence 52, 63-69. (abstract available)
190. Darke, S., Kaye, S., McKetin, R., & Duflou, J. (2008). Major physical and psychological harms of methamphetamine use. Drug and Alcohol Review, 27(3), 253-262.
191. Darke, S., Kaye, S. & Ross, J. (1999). Transitions between the injection of heroin and amphetamines. Addiction 94, 1795-1803.
192. Darke, S., Kaye, S. & Ross, J. (2001). Geographical injecting locations among injecting drug users in Sydney, Australia. Addiction 96, 241-246.
193. Darke, S., Kaye, S., & Topp, L. (2002). Cocaine use in New South Wales, Australia, 1996-2000: 5 year monitoring of trends in price, purity, availability and use from the illicit drug reporting system. Drug and Alcohol Dependence 67, 81-88. (abstract available)
194. Darke, S., Kelaher, M., Hall, W., & Flaherty, B. (1996) Characteristics of admissions to residential drug treatment agencies in New South Wales, 1988-1992: Illicit drug problems. Drug and Alcohol Review 15, 127-132.
195. Darke, S., Kelly, E. & Ross, J. (2004). Drug driving among injecting drug users in Sydney, Australia: Prevalence, risk factors and risk perceptions. Addiction 99, 177-185. (abstract available)
196. Darke, S. & Mattick, R.P. (1996). Commentary on Lintzeris et al. Drug and Alcohol Review 15, 197-198.
197. Darke, S., Mattick, R.P. & Degenhardt, L. (2003). The ratio of non-fatal to fatal heroin overdose. Addiction 98, 1169-1171.
198. Darke, S., Mills, K., Ross, J., Teesson, M., Williamson, A., & Havard, A. (2009). Patterns of major depression and drug-related problems amongst heroin users across 36 months. Psychiatric Research 166(1), 7-14.
199. Darke, S., Mills, K., Ross, J., Williamson, A., & Teesson, M. (2009). The aging heroin user: Career length, clinical profile and outcomes across 36 Months. Drug and Alcohol Review 28(3), 243-249.
200. Darke, S. & Ross, J. (1997). Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug and Alcohol Dependence 48, 135-141.
201. Darke, S. & Ross, J. (1997). Overdose risk perceptions and behaviours among heroin users in Sydney, Australia. European Addiction Research 3, 87-92.
202. Darke, S. & Ross, J. (1999). Heroin-related deaths in South Western Sydney, Australia, 1992-96. Drug and Alcohol Review 18, 39-46.
203. Darke, S. & Ross, J. (2000). The use of antidepressants among injecting drug users in Sydney, Australia. Addiction 95, 407-417. (abstract available)
204. Darke, S. & Ross, J. (2000). Fatal heroin overdoses resulting from non-injecting routes of administration, NSW, Australia, 1992-1996. Addiction 95, 569-573. (abstract available)
205. Darke, S. & Ross, J. (2000). Heroin-related deaths in regional New South Wales. 1992-96. Drug and Alcohol Review 19, 35-40. (abstract available)
206. Darke, S. & Ross, J. (2001). The relationship between suicide and heroin overdose among methadone maintenance patients in Sydney, Australia. Addiction 96, 1443-1453. (abstract available)
207. Darke, S. & Ross, J. (2002). Suicide among heroin users: Rates, risk factors and methods. Addiction 97, 1383-1394.
208. Darke, S., Ross, J., & Cohen, J. (1994). The use of benzodiazepines among regular amphetamine users. Addiction 89, 1683-1690.
209. Darke, S., Ross, J., Cohen, J., Hando, J., & Hall, W. (1995). Injecting and sexual risk-taking behaviour among regular amphetamine users. AIDS Care 7, 17-24.
210. Darke, S., Ross, J., & Hall, W. (1995). Benzodiazepine use among injecting heroin users. Medical Journal of Australia 162, 645-647.
211. Darke, S., Ross, J., & Hall, W. (1996). Overdose among heroin users in Sydney, Australia I. Prevalence and correlates of non-fatal overdose. Addiction 91, 405-411. (abstract available)
212. Darke, S., Ross, J., & Hall, W. (1996). Overdose among heroin users in Sydney, Australia II. Responses to overdose. Addiction 91, 413-417. (abstract available)
213. Darke, S., Ross, J., & Hall, W. (1996). Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug and Alcohol Dependence 43, 191-198.
214. Darke, S., Ross, J. & Kaye, S. (2001). Physical injecting sites among injecting drug users in Sydney, Australia. Drug and Alcohol Dependence 62, 77-82. (abstract available)
215. Darke, S., Ross, J. & Lynskey, M. (2003). The relationship of conduct disorder to attempted suicide and drug use history among methadone maintenance patients. Drug and Alcohol Review 22, 21-25. (abstract available)
216. Darke, S., Ross, J., Lynskey, M., & Teesson, M. (2004). Attempted suicide among entrants to three treatment modailities for heroin dependence in the Australian Treatment Outcome Study (ATOS): Prevalence and risk factors. Drug and Alcohol Dependence 73, 1-10. (abstract available)
217. Darke, S., Ross, J., Mills, K. L., Williamson, A., Havard, A., & Teesson, M. (2007). Patterns of sustained heroin abstinence amongst long-term, dependent heroin users: 36 months findings from the Australian Treatment Outcome Study (ATOS). Addictive Behaviors, 32(9), 1897-1906.
218. Darke, S., Ross, J., & Teesson, M. (2005). Twelve-month outcomes for heroin dependnce treatments: Does route of administration matter? Drug and Alcohol Review 24, 165-172.
219. Darke, S., Ross, J. & Teesson, M. (2007). The Australian Treatment Outcome Study (ATOS): What have we learnt about treatment for heroin dependence? Drug and Alcohol Review 26, 49-54.
220. Darke, S., Ross, J., Teesson, M., Ali, R., Cooke, R., Ritter, A., & Lynskey, M. (2005). Factors associated with 12 months continuous heroin abstinence: Findings from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment 28, 255-263.
221. Darke, S., Ross, J., Teesson, M., & Lynksey, M. (2003). Health service utilization and benzodiazepine use among heroin users: Findings from the Australian Treatment Outcome Study (ATOS). Addiction 98, 1129-1135. (abstract available)
222. Darke, S., Ross, J., Williamson, A., Mills, K., Havard, A., & Teesson, M. (2007). Patterns and correlates of attempted suicide by heroin users over a 3-year period: Findings from the Australian Treatment Outcome Study. Drug and Alcohol Dependence 87, 146-152.
223. Darke, S., Ross, J., Williamson, A., Mills, K., Havard, A., & Teesson, M. (2007). Borderline personality disorder and persistently elevated levels of risk in 36-month outcomes for the treatment of heroin dependence. Addiction 102, 1140-1146.
224. Darke, S., Ross, J., Williamson, A., Mills, K. L., Havard, A., & Teesson, M. (2008). Injecting and noninjecting heroin administration: Transitions and treatment outcomes across 36 months. Journal of Drug Issues, 38(2), 543-557.
225. Darke, S., Ross, J., Williamson, A., & Teesson, M. (2005). The impact of borderline personality disorder on 12-month outcomes for the treatment of heroin dependence. Addiction, 100(8), 1121-1130.
226. Darke, S., Ross, J., Zador, D., & Sunjic, S. (2000). Heroin-related deaths in New South Wales. 1992-96. Drug and Alcohol Dependence 60, 141-150. (abstract available)
227. Darke, S., Sims, J., McDonald, S., & Wickes, W. (2000). Cognitive impairment among methadone maintenance patients. Addiction 95, 687-696. (abstract available)
228. Darke, S., Sunjic, S., Zador, D., & Prolov, T. (1997). A comparison of blood toxicology of heroin-related deaths and current heroin users in Sydney, Australia. Drug and Alcohol Dependence 47, 45-53. (abstract available)
229. Darke, S., Swift, W., & Hall, W. (1994). Prevalence, severity and correlates of psychological morbidity among methadone maintenance clients. Addiction 89 (2), 211-217.
230. Darke, S., Swift, W., Hall, W., & Ross, M. (1994). Predictors of injecting and injecting risk-taking behaviour among methadone maintenance clients. Addiction 89, 331-336.
231. Darke, S., Swift, W., Hall, W., & Ross, M. (1993). Drug use, HIV risk-taking and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug and Alcohol Dependence 34, 67-70.
232. Darke, S., Topp, L., Kaye, S. & Hall, W. (2002). Heroin use in New South Wales, Australia, 1996-2000: 5 year monitoring of trends in price, purity, availability and use from the Illicit Drug Reporting System. Addiction 97, 179-186. (abstract available)
233. Darke, S., Topp, L., & Ross, J. (2002). The injection of methadone and benzodiazepines among Sydney IDU 1996-2000: 5 year monitoring of trends from the Illicit Drug Reporting System (IDRS). Drug and Alcohol Review 21, 35-40. (abstract available)
234. Darke, S., Ward, J., Zador, D., & Swift, G. (1991). A scale for measuring the health status of opiate users. British Journal of Addiction 86, 1317-1322.
235. Darke, S., Williamson, A., Ross, J., Mills, K., Havard, A., & Teesson, M. (2007). Patterns of nonfatal heroin overdose over a 3-year period: Findings from the Australian Treatment Outcome Study. Journal of Urban Health 84, 283-291.
236. Darke, S., Williamson, A., Ross, J., & Teesson, M. (2005). Attempted suicide among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Dependence 78, 177-186.
237. Darke, S., Williamson, A., Ross, J., & Teesson, M. (2005). Non-fatal heroin overdose, treatment exposure and client characteristics: Findings from the Australian treatment outcome study (ATOS). Drug and Alcohol Review 24, 425-432. (abstract available)
238. Darke, S., Williamson, A., Ross, J., & Teesson, M. (2006). Residential rehabilitation for the treatment of heroin dependence: Sustained heroin abstinence and drug-related problems 2 years after treatment entrance. Addictive Disorders & Their Treatment 5, 9-18.
239. Darke, S., Williamson, A., Ross, J., & Teesson, M. (2006). Reductions in heroin use are not associated with increases in other drug use: 2-year findings from the Australian Treatment Outcome Study. Drug and Alcohol Dependence 84, 201-205.
240. Darke, S., Williamson, A., Ross, J., Teesson, M., & Lynskey, M. (2004). Borderline personality disorder, antisocial personality disorder and risk-taking among heroin users: Findings from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Dependence 74, 77-83.
241. Darke, S., Wodak, A., Hall, W., Heather, N., & Ward, J. (1992). Prevalence and predictors of psychopathology among opioid users. British Journal of Addiction 87, 771-776.
242. Darke, S. & Zador, D. (1996). Fatal heroin overdose: A review. Addiction 91, 1765-1772.
243. Darke, S., Zador, D., & Sunjic, S. (1997). Heroin-related deaths in south-western Sydney (letter to the editor). Medical Journal of Australia 167, 107.
244. Dawe, S., Rees, V. & Mattick, R. (2002). Efficacy of moderation-oriented cue exposure for problem drinkers: A randomized controlled trial. Journal of Consulting and Clinical Psychology 70, 1045-1050.
245. Davoli, M., Ferri, M., Ali, R., Auriacombe, M., Faggiano, F., Mattick, R.P., Farrell, M. & Ling, W. (2000). The Cochrane Review Group on drugs and alcohol. Addiction 95, (10) 1473-1474.
246. Day, C., Collins, L., Degenhardt, L., Thetford, C., & Maher, L. (2004). Reliability of heroin users’ reports of drug use behaviour using a 24 month timeline follow-back technique to assess the impact of the Australian heroin shortage. Addiction Research and Theory 12, 433-443.
247. Day, C., Conroy, E., Lowe, J., Page, J., & Dolan, K. (2006).Patterns of drug use and associated harms among rural injecting drug users: Comparisons with metropolitan injecting drug users. Australian Journal of Rural Health 14, 120-125.
248. Day, C., Degenhardt, L., Gilmour, S., & Hall, W. (2004). Effects of reduction in heroin supply on injecting drug use: Analysis of data from needle and syringe programmes. BMJ 329,428-429.
249. Day, C., Degenhardt, L., Gilmour, S., & Hall, W. (2005). The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia. BMC Public Health 5:84.
250. Day, C., Degenhardt, L.. & Hall, W. (2006). Documenting the heroin shortage in New South Wales. Drug and Alcohol Review 25, 297 – 305.
251. Day, C., Degenhardt, L.. & Hall, W. (2006). Changes in the initiation of heroin use after a reduction in heroin supply. Drug and Alcohol Review 25, 307-313.
252. Day, C. & Dolan, K. (2006). Correlates of hepatitis C testing among heroin injectors in Sydney. Health Promotion Journal of Australia 17, 70-72.
253. Day, C., Jayasuriya, R. & Stone, G. (2004). Hepatitis C-related discrimination in New South Wales. Australian Health Review 27, 58-61.
254. Day, C., Nassirimanesh, B., Shakeshaft, A., & Dolan, K. (2006). Patterns of drug use among a sample of drug users and injecting drug users attending a GP clinic in Iran. Harm Reduction Journal 3:2.
255. Day, C., Ross, J., Dietze, P., & Dolan, K. (2005). Initiation to heroin injecting among heroin users in Sydney, Australia: Cross sectional survey. Harm Reduction Journal 2:2.
256. Day, C., Ross, J. & Dolan, K. (2003). Hepatitis C-related discrimination among heroin users in Sydney: Drug user or hepatitis C discrimination? Drug and Alcohol Review 22, 317-321. (abstract available)
257. Day, C., Ross, J. & Dolan, K. (2004). Characteristics of Aboriginal Injecting Drug Users in Sydney, Australia: Prison history, hepatitis C status and drug treatment experiences. Journal of Ethnicity in Substance Abuse 2, 51-58. (abstract available)
258. Day, C. & Topp, L. (2003). Safety in drug and alcohol research (Editorial). Addiction 98, 1641-1643.
259. Day, C., Topp, L., Rouen, D., Darke, S., Hall, W., & Dolan, K. (2003). Decreased heroin availability in Sydney in early 2001. Addiction 98, 93-95. (abstract available)
260. Day, C., White, B., Ross, J. & Dolan, K. (2003). Poor knowledge and low coverage of hepatitis B vaccination among injecting drug users in Sydney. Australian and New Zealand Journal of Public Health 27, 558.
261. Dean, A.J., Bell, J., Christie, M.J., & Mattick, R.P. (2004). Depressive symptoms during buprenorphine versus methadone maintenance: Findings from a randomized controlled trial. European Psychiatry 19, 510-513.
262. De Burgh, S., Mant, A., Mattick, R.P., Donnelly, N., Hall, W., & Bridges-Webb, C. (1994). A controlled trial of educational visiting to improve benzodiazepine prescribing in general practice. Australian Journal of Public Health 19, 142-148.
263. Degenhardt, L. (2000). Interventions for people with alcohol use disorders and an intellectual disability: A review of the literature. Journal of Intellectual & Developmental Disability 25, 135-146. (abstract available)
264. Degenhardt, L. (2003). The link between cannabis use and psychosis: Furthering the debate (Editorial). Psychological Medicine 33, 3-6.
265. Degenhardt, L. (2003). GHB: Un analisis. Adicciones 15 (Supl 2), 167-177.
266. Degenhardt, L. (2005). Illicit drug users respond to price changes (book review). Nordic Studies on Alcohol and Drugs 22, 185-188.
267. Degenhardt, L. (2005). Drug use and risk behaviour among regular ecstasy users: Does sexuality make a difference? Culture, Health & Sexuality 7,
599-614.
268. Degenhardt, L., Baker, A., & Maher, L. (2008). Methamphetamine: Geographic areas and populations at risk, and emerging evidence for effective interventions. Drug and Alcohol Review, 27(3), 217-219.
269. Degenhardt, L., Barker, B. & Topp, L. (2004). Patterns of ecstasy use in Australia: Findings from a national household survey. Addiction 99, 187-195.
270. Degenhardt, L., Black, E., Breen, C., Bruno, R., Kinner, S., Roxburgh, A., Fry, C., Jenkinson, R., Ward, J., Fetherston, J., Weekley, J., & Fischer, J. (2006). Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug and Alcohol Review 25, 403-412.
271. Degenhardt, L., Bohnert, K. M., & Anthony, J. C. (2007). Case ascertainment of alcohol dependence in general population surveys: 'Gated' versus 'ungated' approaches. International Journal of Methods in Psychiatric Research, 16, 111-123.
272. Degenhardt, L., Bohnert, K. M., & Anthony, J. C. (2008). Assessment of cocaine and other drug dependence in the general population: "Gated" versus "ungated" approaches. Drug and Alcohol Dependence, 93(3), 227-232.
273. Degenhardt, L., Cheng, H. & Anthony, J.C. (2007). Assessing cannabis dependence in community surveys: Methodological issues. International Journal of Methods in Psychiatric Research 16, 43–51.
274. Degenhardt, L., Chiu, W. T., Conway, K., Dieker, L., Glantz, M., Kalaydjian, A., et al. (2009). Does the ‘gateway’ matter? Associations between the order of drug use initiation and the development of drug dependence in the National Comorbidity Study Replication. Psychological Medicine 39(1), 157-167
275. Degenhardt, L., Chiu, W. T., Sampson, N., Kessler, R. C., Anthony, J. C., Angermeyer, M., et al. (2008). Toward a global view of alcohol, tobacco, cannabis, and cocaine use: Findings from the WHO World Mental Health Surveys. Plos Medicine, 5(7), 1053-1067.
276. Degenhardt, L., Coffey, C., Carlin, J.B., Moran, P., & Patton, G.C. (2007). Who are the new amphetamine users? A 10-year prospective study of young Australians. Addiction 102, 1269–1279.
277. Degenhardt, L., Coffey, C., Carlin, J.B., Swift, W., & Patton, G.C. (2008). Are diagnostic orphans at risk of developing cannabis abuse or dependence? Four-year follow-up of young adult cannabis users not meeting diagnostic criteria. Drug and Alcohol Dependence 92, 86–90.
278. Degenhardt, L., Coffey, C., Moran, P., Carlin, J.B., & Patton, G. (2007). The predictors and consequences of adolescent amphetamine use: Findings from the Victoria Adolescent Health Cohort Study. Addiction 102, 1076–1084.
279. Degenhardt, L., Conigrave, K., Wutzke, S., & Saunders, J. (2001). The validity of an Australian modification of the AUDIT questionnaire. Drug and Alcohol Review 20, 143-153. (abstract available)
280. Degenhardt, L., Conroy, E., Day, C., Gilmour, S., & Hall, W. (2005). The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. Drug and Alcohol Dependence 79, 129-135.
281. Degenhardt, L., Conroy, E., Gilmour, S., & Collins, L. (2005). The effect of a reduction in heroin supply in Australia upon drug distribution and acquisitive crime. British Journal of Criminiology 45, 2-24.
282. Degenhardt, L., Conroy, E., Gilmour, S., & Hall, W. (2005). The effect of a reduction in heroin supply on fatal and non-fatal drug overdoses in New South Wales, Australia. Medical Journal of Australia 182, 20-23.
283. Degenhardt, L., Darke, S., & Dillon, P. (2002). GHB use among Australians: Characteristics, use patterns and associated harms. Drug and Alcohol Dependence 67, 89-94. (abstract available)
284. Degenhardt, L., Darke, S. & Dillon, P. (2003). The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users. Addiction 98, 199-204. (abstract available)
285. Degenhardt, L., Day, C., Conroy, E., & Gilmour, S. (2006). Examining links between cocaine use and street-based sex work in New South Wales, Australia. The Journal of Sex Research 43, 107-114.
286. Degenhardt, L., Day, C., Conroy, E., Gilmour, S., & Hall, W. (2005). Age differentials in the impacts of reduced heroin: Effects of a ‘heroin shortage’ in NSW, Australia. Drug and Alcohol Dependence 79, 397-404.
287. Degenhardt, L., Day, C., Dietze, P., Pointer, S., Conroy, E., Collins, L., & Hall, W. (2005). Effects of a sustained heroin shortage in three Australian states. Addiction 100, 908-920.
288. Degenhardt, L., Day, C., Gilmour, S., & Hall, W. (2005). Patterns of illicit drug use in NSW, Australia following a reduction in heroin supply. International Journal of Drug Policy 16, 300-307.
289. Degenhardt, L., Day, C., Gilmour, S., & Hall, W. (2006). The ‘lessons’ of the Australian ‘heroin shortage’. Substance Abuse, Treatment, Prevention and Policy 1:11.
290. Degenhardt, L., Day, C., Hall, W., Conroy, E., & Gilmour, S. (2005). Was an increase in cocaine use among injecting drug users in New South Wales, Australia, accompanied by an increase in violent crime? BMC Public Health 5:40.
291. Degenhardt, L., Dillon, P., Duff, C., & Ross, J. (2006). Driving, drug use behaviour and risk perceptions of nightclub attendees in Victoria, Australia. International Journal of Drug Policy 17, 41-46.
292. Degenhardt, L., & Dunn, M. (2008). The epidemiology of GHB and ketamine use in an Australian household survey. International Journal of Drug Policy, 19(4), 311-316.
293. Degenhardt, L., Gascoigne, M., & Howard, J. (2002). Young people’s drug use when heroin is less available. Youth Studies Australia 21,11-16. (abstract available)
294. Degenhardt, L. Gibson, A., Mattick, R.P. & Hall, W. (2008). Depot naltrexone use for opioid dependence in Australia: Large-scale use of an unregistered medication in the absence of data on safety and efficacy (Editorial). Drug and Alcohol Review 27, 1-3.
295. Degenhardt, L. & Hall, W. (2001). The association between psychosis and problematical drug use among Australian adults: Findings from the National Survey of Mental Health and Well-Being. Psychological Medicine 31, 659-668. (abstract available)
296. Degenhardt, L. & Hall, W. (2001) The relationship between tobacco use, substance use disorders and mental health: Results from the National Survey of Mental Health and Well-being. Nicotine and Smoking Research 3, 225-234.
297. Degenhardt, L. & Hall, W. (2002). Cannabis and psychosis. Current Psychiatry Reports 4, 191-196. (abstract available)
298. Degenhardt, L. & Hall, W. (2003). Patterns of co-morbidity between alcohol use and other substance use in the Australian population. Drug and Alcohol Review 22, 7-13. (abstract available)
299. Degenhardt, L. & Hall, W. (2006). Is cannabis use a contributory cause of psychosis? The Canadian Journal of Psychiatry 51, 556-565.
300. Degenhardt, L. & Hall, W. (2006). Canadian heroin supply and the Australian ‘heroin shortage’ (letter to the editor). Addiction 101, 1666-1668.
301. Degenhardt, L. & Hall, W. (2007). Cannabis-induced psychosis among Aboriginal Canadians of the Northwest Territories (letter to the editor). Canadian Journal of Psychiatry 52, 13-14.
302. Degenhardt, L. & Hall, W. (2007). The relationship between cannabis use and psychosis: Epidemiological evidence and biological plausibility. Advances in Schizophrenia and Clinical Psychiatry 3, 2-7.
303. Degenhardt, L., & Hall, W. (2008). Australian heroin seizures and the causes of the 2001 heroin shortage. International Journal of Drug Policy, 19(4), 293-294.
304. Degenhardt, L., & Hall, W. (2008). The adverse effects of cannabinoids: Implications for use of medical marijuana. Canadian Medical Association Journal, 178(13), 1685-1686.
305. Degenhardt, L. Hall, W., & Adelstein, B. (2001). Ambulance calls to suspected overdoses: New South Wales patterns July 1997 to June 1999. Australian and New Zealand Journal of Public Health 27, 447-450. (abstract available)
306. Degenhardt, L., Hall, C., Day, C., Dietze, P., Collins, L., & Pointer, S. (2005). Mapping the consequences of an unanticipated drug supply change of uncertain origins: Responses to the commentaries. Addiction 100, 930-932.
307. Degenhardt, L., Hall, W., & Lynskey, M. (2000). Cohort trends in the age of initiation of drug use in Australia. Australian and New Zealand Journal of Public Health 24, 421-426. (abstract available)
308. Degenhardt, L., Hall, W., & Lynskey, M. (2000). Cohort trends in the age of initiation of drug use in Australia. Australian and New Zealand Journal of Public Health 24, 421-426.
309. Degenhardt, L., Hall, W., & Lynskey, M. (2001). Ambulance calls to suspected overdoses: New South Wales patterns July 1997 to June 1999. Australian and New Zealand Journal of Public Health 25, 447-450.
310. Degenhardt, L., Hall, W., & Lynskey, M. (2001). The relationship between cannabis use and other substance use in the general population. Drug and Alcohol Dependence 64, 319-327. (abstract available)
311. Degenhardt, L., Hall, W., & Lynskey, M. (2001). Alcohol, cannabis and tobacco use among Australians: A comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction 96, 1603-1614. (abstract available)
312. Degenhardt, L., Hall, W., & Lynskey, M. (2001). Co-morbidity between alcohol, tobacco and cannabis use: Reply to David Ferguson (letter to the editor). Addiction 96, 1862.
313. Degenhardt, L., Hall, W., & Lynskey, M. (2001). The relationship between cannabis use and other substance use in the general population. Drug and Alcohol Dependence 64, 319-327.
314. Degenhardt, L., Hall, W., & Lynskey, M. (2001). The relationship between cannabis use, depression and anxiety among Australian adults: Findings from the National Survey of Mental Health and Well-Being. Social Psychiatry and Psychiatric Epidemiology 36, 219-227. (abstract available)
315. Degenhardt, L., Hall, W. & Lynskey, M. (2003). Testing hypotheses about the relationship between cannabis use and psychosis. Drug and Alcohol Dependence 71, 37-48. (abstract available)
316. Degenhardt, L., Hall, W. & Lynskey, M. (2003). Exploring the association between cannabis use and depression. Addiction 98, 1493-1504. (abstract available)
317. Degenhardt, L., Hall, W., Roxburgh, A., & Mattick, R.P. (2007). UK classification of cannabis: Is a change needed and why? The Lancet 370, 1541.
318. Degenhardt, L., Hall, W., & Warner-Smith, M. (2006). Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sexually Transmitted Infections 82, iii56-iii63.
319. Degenhardt, L., Kinner, S. A., Roxburgh, A., Black, E., Bruno, R., Fetherston, J., et al. (2008). Drug use and risk among regular injecting drug users in Australia: Does age make a difference? Drug and Alcohol Review, 27(4), 357-360.
320. Degenhardt, L., Knox, S., Barker, B., Britt, H., & Shakeshaft, A. (2005). The management of alcohol, tobacco and illicit drug use problems by general practitioners in Australia. Drug and Alcohol Review 24, 499-506.
321. Degenhardt, L., Lynskey, M., Coffey, C., & Patton, G. (2002). ‘Diagnostic orphans’ among young adult cannabis users: Persons who report dependence symptoms but do not meet diagnostic criteria. Drug and Alcohol Dependence 67, 205-212. (abstract available)
322. Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T. & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug and Alcohol Dependence, 105, 9-15.
323. Degenhardt, L., Reuter, P., Collins, L. & Hall, W. (2005). Evaluating explanations of the Australian ‘heroin shortage’. Addiction 100, 459-469.
324. Degenhardt, L., Roxburgh, A. & Barker, B. (2005). Underlying causes of cocaine, amphetamine and opioid related deaths in Australia. Journal of Clinical Forensic Medicine 12, 187-195.
325. Degenhardt, L., Roxburgh, A., Black, E., Campbell, G., Bruno, R., & Kinner, S. (2008). The epidemiology of methamphetamine use and harm in Australia. Drug and Alcohol Review, 27(3), 243-252
326. Degenhardt, L., Roxburgh, A., & McKetin, R. (2007). Hospital separations for cannabis- and methamphetamine-related psychotic episodes in Australia. Medical Journal of Australia, 186, 342-345.
327. Degenhardt, L., Roxburgh, A., Van Beek, I, Hall, W.D., Robinson, M.K.F., Ross J., Mant, A. (2008). The effects of the market withdrawal of temazepam gel capsules on benzodiazepine injecting in Sydney, Australia. Drug and Alcohol Review, 27(2), 145-151.
328. Degenhardt, L., Tat Chiu, W., Sampson, N., Kessler, R.C., & Anthony, J.C. (2007). Epidemiological patterns of extra-medical drug use in the United States: Evidence from the National Comorbidity Survey Replication, 2001–2003. Drug and Alcohol Dependence 90, 210-223.
329. Degenhardt, L., Tennant, C., Gilmour, S., Schofield, D., Nash, L., Hall, W., & McKay, D. (2007). The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: Findings from a 10-month prospective study. Psychological Medicine 37, 927–934.
330. Degenhardt, L. & Topp, L. (2003). ‘Crystal meth’ use among polydrug users in Sydney’s dance party subculture: Characteristics, use patterns and associated harms. International Journal of Drug Policy 14, 17-24. (abstract available)
331. Degenhardt, L, Topp, L. & Day, C. (2003). Issues surrounding the detection of a reduction in drug supply: The heroin shortage in Australia in 2001. Bulletin On Narcotics Volume LV, Nos 1 and 2, 2003. The practice of drug abuse epidemiology. Vienna: United Nations Office on Drugs and Crime. (abstract available)
332. Dierker, L., He, J., Kalaydjian, A., Swendsen, J., Degenhardt, L., Glantz, M., Conway, K., Anthony, J., Chiu, W. T., Sampson, N. A., Kessler, R., & Merikangas, K. (2008). The Importance of Timing of Transitions for Risk of Regular Smoking and Nicotine Dependence. Annals of Behavioral Medicine, 1-6.
333. Digiusto, E., Lintzeris, N., Breen, C., Kimber, J., Mattick. R.P., Bell, J., Ali, R., & Saunders, J.B. (2005). Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. Addictive Behaviours 30, 443-456.
334. Digiusto, E., Mattick, R.P., Kimber, J., O’Brien, S., Doran, C., Henderson, N., & Breen, C. (2001). National evaluation of pharmacotherapies for opioid dependence – why have we done it? (Editorial). Drug and Alcohol Review 20, 139-141.
335. Digiusto, E., Panjari, M., Gibson, A., Rea, F., & NEPOD Research Group. (2006). Follow-up difficulty: Correlates and relationship with outcome in heroin dependence treatment in the NEPOD study. Addictive Behaviors 31, 1201-1210.
336. Digiusto, E., Shakeshaft, Mattick, R.P., & NEPOD Research Group. (2006). Effects of pharmacotherapies for opioid dependence on participants' criminal behaviour and expenditure on illicit drugs: An Australian National Evaluation (NEPOD). Australian and New Zealand Journal of Criminology 39, 171-189.
337. Digiusto, E., Shakeshaft, A.P., Ritter A., O’Brien, S., Mattick, R.P., & NEPOD Research Group. (2004). Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 99, 450-460.
338. Dillon, P. (2005). Over The Influence, The Harm Reduction Guide for Managing Drugs and Alcohol (book review). Drug and Alcohol Review 24, 290-291.
339. Dillon, P. (1998). Proactive or sensationalist?: The media and harm reduction. International Journal of Drug Policy 9, 175-179. (abstract available)
340. Dillon, P., Copeland, J. & Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug and Alcohol Dependence 69, 23-28. (abstract available)
341. Dillon, P., Copeland, J. & Peters, R. (1999). Exploring the relationship between male homo/bisexuality, body image and steroid use. Culture, Health and Sexuality 1, 317-327. (abstract available)
342. Dillon, P. & Degenhardt, L. (2001). Ketamine and GHB: New trends in club drug use? Journal of Substance Use 6, 11-15. (abstract available)
343. Dillon, P., Goldspink-Lord, L., & Parkhill, N. (1996). Sex, drugs and just say no: A media perspective. International Journal of Drug Policy 7, 183-186. (abstract available)
344. Dillon, P., & Singleton, M. (1996). Anabolic Steroids. Policing Issues and Practice Journal 4, 24-31.
345. Dillon, P. & Singleton, M. (1999). Cannabis. Policing Issues and Practice Journal 7, 1- 9.
346. Dolan, K. (1989). HIV and AIDS - Intravenous drug use in New South Wales, Australia. International Journal of Drug Policy 1, 22-26.
347. Dolan, K. (1991). Testing saliva for HIV. International Jounal of Drug Policy 2, 3.
348. Dolan, K. (1993). Drug injectors in prison and the community in England. International Journal of Drug Policy 4, 179-183.
349. Dolan, K. (1994). Sex in the Slammer. National AIDS Bulletin 8, 12-13.
350. Dolan, K. (1997). AIDS, drugs and risk behaviour in prison: State of the art. International Journal of Drug Policy 8, 5-17.
351. Dolan, K. (1997/98). Evidence about HIV transmission in prisons. Canadian HIV/AIDS Policy & Law Newsletter, 3/4, 32-35.
352. Dolan, K. (1999). Injecting rooms in Switzerland. NSW Public Health Bulletin 10, 59-60.
353. Dolan, K. (2001). Can hepatitis C transmission be reduced in Australian prisons? Medical Journal of Australia 174, 378-379.
354. Dolan, K. (2009). Prison Research. Addiction 104(2), 223-223.
355. Dolan, K., Clement, N., Rouen, D., Rees, V., Shearer, J., & Wodak, A. (2004). Can drug injectors be encouraged to adopt non-injecting routes of administration (NIROA) for drugs? Drug and Alcohol Review 23, 281-286.
356. Dolan, K., Donoghoe, M. & Stimson, G.V. (1990). Drug injecting and syringe sharing in custody and the community: An exploratory survey of HIV risk behaviour. The Howard Journal of Criminal Justice 29, 177-186.
357. Dolan, K.A., Hall, W., & Wodak, A. (1996). Methadone maintenance reduces injecting in prison. British Medical Journal 312, 1162.
358. Dolan, K., Hall, W., Wodak, A., & Gaughwin, M. (1994). Evidence of HIV transmission in an Australian prison (A letter to the editor). Medical Journal of Australia 160, 734.
359. Dolan, K., Kimber, J., Fry, C., Fitzgerald, J., McDonald, D., & Trautmann, F. (2000). Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia, Drug and Alcohol Review 19, 337-346. (abstract available)
360. Dolan, K., Kite, B., Black, E. Aceijas, C., Stimson, G.V. for the Reference Group on HIV/AIDS Prevention and Care among Injecting Drug Users in Developing and Transitional Countries. (2007). HIV in prison in low-income and middle-income countries. Lancet 7, 32-41.
361. Dolan, K. & Larney, S. (2006). HIV in prison in Asia and the Pacific. Development Bulletin 69, 72-74.
362. Dolan, K., Larney, S., & Wodak, A. (2007). The integration of harm reduction into abstinence-based therapeutic communities: A case study of We Help Ourselves. Asian Journal of Counselling, 14(1 & 2), 1-19.
363. Dolan, K., Lowe, D. & Shearer, J. (2004). Evaluation of the condom distribution program in NSW prisons, Australia. Journal of Law, Medicine and Ethics 32, 124-128.
364. Dolan, K. MacDonald, M. & Silins, E. (2005). Needle and syringe programs: A review of the evidence. Canberra: Australian Government Department of Health and Ageing.
365. Dolan, K., Murdo, B. & White, B. (2004). HIV education in a Siberian prison colony for drug dependent males. International Journal for Equity in Health 3, 3-7.
366. Dolan, K. & Niven, H. (2005). A review of HIV prevention among young injecting drug users: A guide for researchers. Harm Reduction Journal 2:5.
367. Dolan, K. & Rouen, D. (2003). Evaluation of an educational comic on harm reduction for prison inmates in New South Wales. International Journal of Forensic Psychology 1, 138-141.
368. Dolan, K., Rouen, D. & Kimber, J. (2004). An overview of the use of urine, hair, sweat and saliva to detect drug use. Drug and Alcohol Review 23, 213-217.
369. Dolan, K., Rutter, S. & Wodak, A. (2003). Prison-based syringe exchange programmes: A review of international research and development. Addiction 98, 153-158. (abstract available)
370. Dolan, K., Rutter, S., Wodak, A., Hall, W., Maher, L., & Dixon, D. (1996). Is syringe exchange feasible in a prison setting? Medical Journal of Australia 164, 508.
371. Dolan, K., Shearer, J., MacDonald, M., Mattick, R.P., Hall, W., & Wodak, A.D. (2003). A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug and Alcohol Dependence 72, 59-65. (abstract available)
372. Dolan, K., Shearer, J., White, B., Zhou, J., Kaldor, J., & Wodak, A. (2005). Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection. Addiction 100, 820-828.
373. Dolan, K. & Silins, E. (2005). Needle and syringe programs: Your questions answered. Canberra: Australian Government Department of Health and Ageing.
374. Dolan, K.A., Stimson, G.V., & Donoghoe, M.C. (1993). Reductions in HIV risk behaviour and stable HIV prevalence in syringe-exchange clients and other injectors in England. Drug and Alcohol Review 12, 133-42.
375. Dolan, K. & Wodak, A. (1996). An international review of methadone provision in prisons. Addictions Research 4, 85-97.
376. Dolan, K. & Wodak, A. (1999). HIV transmission in a prison system in an Australian state. Medical Journal of Australia 171, 14-17. (abstract available)
377. Dolan, K., Wodak, A., & Hall, W. (1998) Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug and Alcohol Review 17, 153-158.
378. Dolan, K., Wodak, A. & Hall, W. (1998). A bleach program for inmates in NSW: An HIV prevention strategy. Australian and New Zealand Journal of Public Health 22, 838-840.
379. Dolan, K., Wodak, A. & Hall, W. (1999). HIV risk behaviour and prevention in prison: A bleach programme for inmates in NSW. Drug and Alcohol Review 18, 139-144. (abstract available)
380. Dolan K, Wodak A, Hall, Gaughwin M & Rae F. (1996). Risk behaviour of IDUs before, during and after imprisonment in NSW. Addiction Research 4, 151-60.
381. Dolan, K., Wodak, A., Hall., Gaughwin, M & Rae, F. (1996). La Trasmissione dell'infezione da HIV in Carcere. Limitazione del Danno Suppl. ad ASPE 8, 15-19.
382. Dolan, K., Wodak, A., Hall, W., & Kaplan, E. (1998). A mathematical model of HIV transmission in NSW prisons. Drug and Alcohol Dependence 50, 197-202.
383. Dolan, K.A., Wodak, A.D., & Rutter, S.A. (1996). Is syringe exchange feasible in a prison setting ? [letter to the editor (reply)]. Medical Journal of Australia 165, 59.
384. Dolan, K., Wodak, A., & Penny, R. (1995). AIDS behind bars: Preventing HIV spread among incarcerated drug injectors. AIDS 9, 825-832.
385. Donnelly, N., Hall, W., & Christie, P. (1995). The effects of decriminalisation on cannabis use in South Australia 1985-1993. Australian Journal of Public Health 19, 281-287. (abstract available)
386. Donnelly, N., Hall, W., & Christie, P. (2000). Effects of the Cannabis Expiation Notice System on the prevalence of cannabis use in South Australia: Evidence from the National Drug Strategy Household surveys 1985-1995. Drug and Alcohol Review 19, 265-269.
387. Donnelly, N., McManus, P., Dudley, J., & Hall, W. (2000). Impact of increasing the re-supply interval on the seasonality of subscribed prescription use in Australia. Australian and New Zealand Journal of Public Health 24, 503-506.
388. Donoghoe, M,, Dolan, K.A. & Stimson, G.V. (1992). Lifestyle factors and social circumstances of syringe sharing in injecting drug users. British Journal of Addiction 87, 993-1003.
389. Donoghoe, M,, Stimson, G.V. & Dolan, K. (1989). Sexual behaviour of injecting drug users and associated risks of HIV infection for non- injecting sexual partners. AIDS Care 1, 51-58.
390. Donoghoe, M,, Stimson, G.V,, Dolan, K., & Alldritt, L. (1989). Changes in HIV risk behaviour in clients of syringe exchange schemes in England and Scotland. AIDS 3, 267-272.
391. Doran, C. (2008). Economic evaluation of interventions to treat opiate dependence: A review of the evidence. PharmacoEconomics, 26(5), 371-393.
392. Doran, C., Duszynski, K. M., Beilby, J. J., & Mattick, R. P. (2006). Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice. Addictive Behaviors, 31(11), 1947-1958.
393. Doran, C., Fawcett, J., Shakeshaft, A., Shanahan, M., & Mattick, R.P. (2003). New Pharmacotherapies for alcohol dependence: are they being used and what do they cost? Medical Journal of Australia 179, 218.
394. Doran, C. Gascoigne, M., Shakeshaft, A., & Petrie, D. (2006). The consumption of alcohol by Australian adolescents: A comparison of revenue and expenditure. Addictive Behaviours 31, 1919-1928.
395. Doran, C., & Shakeshaft, A. P. (2008). Using taxes to curb drinking in Australia. Lancet, 372(9640), 701-702.
396. Doran, C., Shakeshaft, A. & Fawcett, J. (2004). General practitioners' role in preventive medicine: Scenario analysis using alcohol as a case study. Drug and Alcohol Review 23, 399-404.
397. Doran, C.M., Shakeshaft, A.P., Gates, J., Fawcett, J.E., & Mattick, R.P. (2002). Current prescribing patterns of bupropion in Australia (Letter). Medical Journal of Australia 177, 162.
398. Doran, C., Shakeshaft, A., Hall W., & Dennis, P. (2009). Alcohol industry and government revenue derived from underage drinking by Australian adolescents 2005. Addictive Behaviours 34(1), 75-81.
399. Doran, C., Shanahan, M., Bell, J., & Gibson, A. (2004). A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal. Drug and Alcohol Review 23, 171-175.
400. Doran, C., Shanahan, M., Digiusto, E., O'Brien, S., Mattick, R.P. & the NEPOD Research Group (2006). Cost-effectiveness analysis of maintenance agonist treatments in the NEPOD. Expert Review Pharmacotherapies Outcomes Research 6, 437-446.
401. Doran, C., Shanahan, M., Mattick, R.P., Ali, R., White, J., & Bell, J. (2003). Buprenorphine versus methadone maintenance: A cost effectiveness analysis. Drug and Alcohol Dependence 71, 295-302. (abstract available)
402. Doran, C., Stafford, J., Shanahan, M., & & Mattick, R. P. (2009). Characteristics of Australian smokers using buproion and nicotine-replacement therapies. [Special Report]. Expert Review of Pharmacoeconomics and Outcome Research, 7, 41-47.
403. Doran, C., Stafford, J., Shanahan, M., & Mattick, R. P. (2007). Characteristics of Australian smokers using bupropion and nicotine-replacement therapies. Expert Review of Pharmacoeconomics and Outcomes Research, 7(1), 41-47.
404. Doran, C. Valenti, L., Robinson, M., Britt, H., & Mattick, R.P. (2006). Smoking status of Australian general practice patients and their attempts to quit. Addictive Behaviours 31, 758-766.
405. Dunlap, E., Johnson, B.D., Manwar, A., & Maher, L. (1997). Female crack dealers in New York City: Who they are and what they do? Women and Criminal Justice 8, 25-55.
406. Dunn, M., Topp, L., & L., D. (2009). GHB in Sydney, Australia, 2000-2006: A case study of the EDRS as a strategic early warning system. [Research Paper]. International Journal of Drug Policy, 20, 413-417.
407. Dzialdowski, A., Heather, N., & Crawford, J. (1988). Perceptions of drinkers and abstainers in a sample of Scottish adults. Alcohol and Alcoholism 23, 7-16.
408. Edwards, G., Babor, T., West, R., & Hall, W. (2002). Another mirror shattered: industry origins of a book which claims that nicotine is not addictive. Addiction 97, 1-5.
409. Edwards, G., West, R., Babor, T., & Hall, W. (2001). No switching off the camera: How Addiction will respond to infringements of ethical publishing expectation. Addiction 96, 1391-1392.
410. Edwards, P., Wodak, A., Cooper, D.A., Thompson, I.L., & Penny, R. (1990). The gastroenterological manifestation of AIDS. Australian and New Zealand Journal of Medicine 20, 141-148.
411. Elkins, L. & Richmond, R. (1990). Control can go up in smoke. Diabetes Conquest Spring, 6-9.
412. Farrell, M. & Hall, W. (1998). The Swiss Heroin Trials: Testing alternative approaches. British Medical Journal 316, 639.
413. Farrell, M., Ward, J., Mattick, R., Hall, W., Stimson, G., des Jarlais, D., Gossop, M., & Strang, J. (1994). Methadone maintenance treatment in opiate dependence: A review. British Medical Journal 309, 997-1001.
414. Fawcett, J., Shakeshaft, A.P., Harris, M.F., Wodak, A., Mattick, R.P., & Richmond, R.L. (2004). Using AUDIT to classify patients into Australian Alcohol Guideline categories. Medical Journal of Australia 180, 598.
415. Finney Lamb, C. E., Boers, M., Owens, A., Copeland, J., & Sultana, T. (2008). Exploring experiences and attitudes about health care complaints among pregnant women, mothers and staff at an Opioid Treatment Service. Australian health review : A publication of the Australian Hospital Association, 32(1), 66-75.
416. Flaherty, B., Homel, P., & Hall, W. (1991). Public attitudes towards alcohol control policies. Australian Journal of Public Health 15, 301-306.
417. Freeman, A., Jones, C.G.A., Weatherburn, D.J., Rutter, S., Spooner, C.J., & Donnelly, N. (2005). The impact of the Sydney Medically Supervised Injecting Centre (MSIC) on crime. Drug and Alcohol Review 24, 173-184.
418. Friedman, S.R, De Jong, W., & Wodak, A. (1993). Community development as a response to HIV among drug injectors. AIDS 7(suppl 1), S263-S269.
419. Gallagher, J. & Teesson, M. (2000). Measuring disability, need and outcome in Australian community mental health services. Australian and New Zealand Journal of Psychiatry 34, 850-855.
420. Gaston, J. E., & Vogl, L. (2005). Psychometric properties of the General Well-Being Index. Quality of Life Research, 14(1), 71-75.
421. Gates, P., Copeland, J., Stevenson, R. & Dillon, P. (2007). The influence of product packaging on young people’s ratings of alcohol palatability. Alcohol & Alcoholism 42, 138-142.
422. Gates, J., Post, J., Kaldor, J., Pan, Y., Haber, P., Lloyd, A., Dolan, K., & Hepatitis C Incidence and Transmission in Prison Study Group (2004). Risk factors for hepatitis C infection and perception of antibody status among male prison inmates in the Hepatitis C Incidence and Transmission in Prisons Study cohort, Australia. Journal of Urban Health 81, 448-452.
423. Gaughwin, M., Kliewer, E., Ali, R., Faulkner, C., & Wodak, A. (1993). The prescription of methadone for opiate dependence in Australia, 1985-1991. Medical Journal of Australia 159, 107-108.
424. Gibson, A. (2003). A comparison of buprenorphine treatment in clinic and primary care settings: A randomised trial (In Reply). Medical Journal of Australia 179, 558.
425. Gibson, A., Day, C., & Degenhardt, L. (2005). The impact of illicit drug market changes on health agency operations in Sydney, Australia. Journal of Substance Abuse Treatment 28, 35-40.
426. Gibson, A. & Degenhardt, L. (2007). Mortality related to pharmacotherapies for opioid dependence: A comparative analysis of coronial records. Drug and Alcohol Review 26, 405 – 410.
427. Gibson, A., Degenhardt, L., Day, C., & McKetin, R. (2005). Recent trends in heroin supply to markets in Australia, the United States and Western Europe. International Journal of Drug Policy 16, 193-299.
428. Gibson, A., Degenhardt, L. & Hall, W. (2007). Opioid overdose deaths can occur in patients with naltrexone implants. Medical Journal of Australia 186, 152-153.
429. Gibson, A., Degenhardt, L. & Hall, W. (2007). Opioid overdose deaths can occur in patients with naltrexone implants (In Reply). Medical Journal of Australia 187, 56-57.
430. Gibson, A., Doran, C., Bell, J., Ryan, A., & Lintzeris, N. (2003). A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Medical Journal of Australia 179, 38-42. (abstract available)
431. Gibson, A., Degenhardt, L., Mattick, R. P., Ali, R., White, J., & O'Brien, S. (2008). Exposure to opioid maintenance treatment reduces long-term mortality. Addiction, 103, 462-468.
432. Gibson, A. & Shanahan, M. (2007). Costs and outcomes of treatments for excessive alcohol consumption: Making policy decisions with the available data. Drugs - Education Prevention and Policy 14, 1-17.
433. Gilmour, S., Degenhardt, L., Hall, W., & Day, C. (2006). Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: A general method and example. BMC Medical Research Methodology, 6,16.
434. Gilmour, S., Koch, I., Degenhardt, L., & Day, C. (2006). Identification and quantification of change in Australian illicit drug markets. BMC Public Health 6,200.
435. Glantz, M., Anthony, J. C., Berglund, P. A., Degenhardt, L., Dierker, L., Kalaydjian, A., et al. (2009). Mental disorders as risk factors for later substance dependence: estimates of optimal prevention and treatment benefits. Psychological Medicine 39(8), 1365-1377.
436. Gomel, M., Oldenburg, B., Lemon, J., Owen, N., & Westbrook, F. (1993). Pilot study of the effects of a workplace smoking ban on indices of smoking, cigarette craving, stress and other health behaviours. Psychology and Health 8, 223-229.
437. Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W., & Strang, J. (1995). The Severity of Dependence Scale (SDS) in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90, 607-614.
438. Grabowski, J., Shearer, J., Merrill, J., & Stevens Negus, S. (2004). Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addictive Behaviours 29, 1439-1464.
439. Greeley, J. (1989). Pavlovian conditioning and pain regulation: Insights from pharmacological conditioning with morphine and naloxone. Biological Psychology 28, 41-65.
440. Greeley, J. (1992). The nature of opioid dependence (Editoral). Australian Journal of Psychopharmacology 6, 1.
441. Greeley, J., Le A.D., Poulos, C.X., & Cappell, H. (1988). Paradoxical analgesia induced by naloxone and naltrexone. Psychopharmacology 96, 36-39.
442. Greeley, J., Swift, W., & Heather, N. (1992). Depressed affect as a predictor of increased desire for alcohol in current drinkers of alcohol. British Journal of Addiction 87, 1005-1012.
443. Greeley, J., Swift, W., & Heather, N. (1993). To drink or not to drink?: Assessing conflicting desires in dependent drinkers in treatment. Drug & Alcohol Dependence 32, 169-179.
444. Greeley, J., Swift, W., Prescott, J., & Heather, N. (1993). Reactivity to alcohol-related cues in heavy and light drinkers. Journal of Studies on Alcohol 54, 359-368.
445. Greeley, J. & Westbrook, R.F. (1990). Some effects of exposure to a heat stressor upon the rat’s subsequent reactions to that stressor. Quarterly Journal of Experimental Psychology 42B, 241-265.
446. Grenyer, B.F.S., Williams, G., Swift, W., & Neill, O. (1992). The prevalence of social-evaluative anxiety in opioid users seeking treatment. International Journal of the Addictions 27, 665-673.
447. Griffiths, P. & McKetin, R. (2003). Developing a global perspective on drug consumption patterns and trends – the challenge for drug epidemiology. In Bulletin On Narcotics Volume LV, Nos 1 and 2, 2003. The practice of drug abuse epidemiology. Vienna: United Nations Office on Drugs and Crime. (abstract available)
448. Guinan, J.J., Darke, S., & Gold, J. (1990). The epidemiology of HIV infection and risk behaviour of intravenous drug users: A reply to Donovan et al. (letter to the editor). Medical Journal of Australia 152, 499.
449. Guinan, J.J., Hall, W., Clarke, J.C., & Gold, J. (1992). Alcohol and recreational drug use by HIV-seropositive homosexual men. Drug and Alcohol Review 11, 355-362.
450. Gureje, O., Degenhardt, L., Olley, B., Uwakwee, R., Udofiaf, O., Wakil, A., Adeyemi, O., Bohnert, K.M., & Anthony, J.C. (2007). A descriptive pidemiology of substance use and substance use disorders in Nigeria during the early 21st century. Drug and Alcohol Dependence 91, 1-9.
451. Haber, P.S., Wilson, J.S., Apte, M.V., Hall, W., & Goumas, K. (1994). Lipid intolerance does not account for susceptibility to alcoholic and gallstone pancreatitis. Gastroenterology 106, 742-748.
452. Haber, P. S., Cameron, B., Elliott, L., Teutsch, S., Ffrench, R., Dolan, K., et al. (2007). Correlates of incident HCV infection and seronegative-immune status in high risk, IDU prisoners. Hepatology, 46, 630A-630A.
453. Haber, P.S., Wilson, J.S., McGarity, B.M., Hall, W., Thomas, M.C., & Pirola, R.C. (1991). Alpha-1-antitrypsin phenotypes and alcoholic pancreatitis. Gut 32, 945-948.
454. Hall, W. (1992). The Australian debate about the legalisation of heroin and other illicit drugs. Journal of Drug Issues 22, 563-577.
455. Hall, W. (1993). Perfectionism in the therapeutic appraisal of methadone maintenance. Addiction 88, 1181-1182.
456. Hall, W. (1994). Value for money in addiction services. Addiction 89, 919-923.
457. Hall, W. (1994). The health and psychological effects of cannabis use. Current Issues in Criminal Justice 6, 208-220.
458. Hall, W. (1995). The public health implications of cannabis use. Australian Journal of Public Health 19, 235-242.
459. Hall, W. (1995). What advice should family physicians give their patients about the health effects of cannabis? Australian Family Physician 24, 1237-1240.
460. Hall, W. (1995). Making research more relevant to practice. Drug and Alcohol Review 14, 149-150.
461. Hall, W. (1995). Variations in prohibition: Harm minimisation in Australia and Drug Wars in the USA. Australian and New Zealand Journal of Criminology, Special Supplementary Issue, 74-77.
462. Hall, W. (1996). How can we reduce the number of heroin "overdose" deaths? Medical Journal of Australia 164, 197-198.
463. Hall, W. (1996). Changes in the public perceptions of the health benefits of alcohol use, 1989 to1994. Australian Journal of Public Health 20, 93-95.
464. Hall, W. (1996). Statistical questions. A commentary on Finney et al.'s "the effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects". Addiction 91, 1808.
465. Hall, W. (1996). What have population surveys revealed about substance use disorders and their co-morbidity with other mental disorders? Drug and Alcohol Review 15, 157-170.
466. Hall, W. (1996). Methadone maintenance treatment as a crime control measure. Crime and Justice Bulletin Number 29, June, 1-12.
467. Hall, W. (1997). Marijuana myths, marijuana fact (book review). Science 278, 75.
468. Hall, W. (1997). The recent Australian debate about the prohibition on cannabis use. Addiction 92, 1109-1115.
469. Hall, W. (1997). Highs and lows. Lancet 350, (suppl. III): 1.
470. Hall, W. (1997). The search for an elixir of abstinence. Australian Family Physician 27, S1-S2.
471. Hall, W. (1997). Australia: La nuova sfida e l'overdose. Aspe Disagio Pace Ambiente 16, 6-7.
472. Hall, W. (1997). The role of legal coercion in the treatment of offenders with alcohol and heroin problems. Australian and New Zealand Journal of Criminology 30, 103-120.
473. Hall, W. (1997). Addiction: Highs and lows. Review 1997. Supplement to Lancet December, 20-27.
474. Hall, W. (1997). An ongoing debate. Science 278, 75.
475. Hall, W. (1998). Creating space for a more reasoned debate about drug policy. Policy Options 19, 18-21.
476. Hall, W. (1998). Cannabis and psychosis. Drug and Alcohol Review, 17, 433-444.
477. Hall, W. (1998). The respiratory risks of cannabis smoking. Addiction 93, 1461-1463.
478. Hall, W. (1998). The search for an elixir of abstinence. Australian Family Physician 27, S1-S2.
479. Hall, W. (1999). Patient matching in the treatment of alcohol dependence: Is the null hypothesis still alive and well? Addiction 94, 52-54.
480. Hall, W. (1999) Reducing the toll of opioid overdose deaths in Australia. Drug and Alcohol Review 18, 213-220.
481. Hall, W. (1999) Appraisals of the health effects of cannabis: Ideology and evidence. FAS Drug Policy Analysis Bulletin 7 June, 270.
482. Hall, W. (1999). Opium in Britain: Conflicting and converging interests. Lancet 353, 1449-1450.
483. Hall, W. (1999). Appraisals of the health effects of cannabis: Ideology and evidence. FAS Drug Policy Analysis Bulletin June, Number 7.
484. Hall, W. (2000) Transcending methadone. Lancet 355, 585.
485. Hall, W. (2000) Rolleston revisited. Addiction 95, 1273-1274.
486. Hall, W. (2000) UROD: An Antipodean therapeutic enthusiasm. Addiction 95, 1765-1766.
487. Hall, W. (2000). The cannabis policy debate: Finding a way forward. Canadian Medical Association Journal 162, 1690-1692.
488. Hall, W. (2001). Reducing the harms of cannabis use: The policy debate in Australia. Drug and Alcohol Dependence 62, 163-174.
489. Hall, W. & Babor, T. (2000) Cannabis and public health: assessing the burden. Addiction 95, 485-490.
490. Hall, W., Bell, J., & Carless, J. (1993). Crime and drug use among applicants for methadone maintenance. Drug and Alcohol Dependence 31, 123-129.
491. Hall, W., Carless, J., Homel, P., Flaherty, B., & Reilly, C. (1991). The characteristics of cocaine users among young Sydney adults. Medical Journal of Australia 155, 11-13.
492. Hall, W., Chen, R., & Evans, B. (1995). Characteristics of clients admitted to the Buttery, a therapeutic community, 1980-1992. Drug and Alcohol Review 14, 125-129.
493. Hall, W. & Darke, S. (1997). Prima i vecchi. Aspe Disagio Pace Ambiente 16, 8-10.
494. Hall, W. & Darke, S. (1998). Trends in opiate overdose deaths in Australia 1979-1995. Drug and Alcohol Dependence 52, 71-77.
495. Hall, W., Darke, S., Ross, M., & Wodak, A. (1993). Patterns of drug use and risk-taking among opioid and amphetamine injecting drug users in Sydney. Addiction 88, 509-516.
496. Hall, W. & Degenhardt, L. (1998). The decline in alcohol disorders with age: Causes and implications. Australasian Journal of Ageing 17, 158-159.
497. Hall, W. & Degenhardt, L. (2000). Cannabis and psychosis. Australian and New Zealand Journal of Psychiatry 34, 26-34. (abstract available)
498. Hall, W. & Degenhardt, L. (2003). Medical marijuana initiatives. Are they justified? How successful are they likely to be? CNS Drugs 17, 689-697. (abstract available)
499. Hall, W. & Degenhardt, L. (2003). Marijuana for medical purposes. New Ethical Journal December, 9-15.
500. Hall, W. & Degenhardt, L. (2006). What are the policy implications of the evidence on cannabis and psychosis? The Canadian Journal of Psychiatry 51, 566-574.
501. Hall, W. & Degenhardt, L. (2007). Prevalence and correlates of cannabis use in developed and developing countries. Current Opinion in Psychiatry 20, 393–397.
502. Hall, W., & Degenhardt, L. (2007). Regulating opioid prescribing to provide access to effective treatment while minimizing diversion: An overdue topic for research. Addiction, 102, 1685-1688.
503. Hall, W., & Degenhardt, L. (2008). Cannabis use and the risk of developing a psychotic disorder. World Psychiatry, 7(2), 68-71.
504. Hall, W., Degenhardt, L., & Currow, D. (2001). Allowing the medical use of cannabis. Medical Journal of Australia 175, 39-40.
505. Hall, W., Degenhardt, L., Gibson, A., & Mattick, R. P. (2008). Response to Degenhardt et al.: 'Depot naltrexone use for opioid dependence in Australia: Large-scale use of an unregistered medication in the absence of data on safety and efficacy'. Drug and Alcohol Review, 27(4), 448-449.
506. Hall, W., Degenhardt, L. & Lynskey, M. (1999). Opioid overdose mortality in Australia, 1964-1997: Birth-cohort trends. Medical Journal of Australia 171, 34-37. (abstract available)
507. Hall, W., Degenhardt, L. & Lynskey, M. (1999). Cohort trends in overdose mortality in Australia 1964-1966: A window on post-war trends in heroin use. Medical Journal of Australia 171, 34-37.
508. Hall, W., Degenhardt, L., & Lynskey, M. (2000). Trends in methadone overdose death in Australia and the United Kingdom 1985-1995. Drug and Alcohol Dependence 57, 247-254.
509. Hall, W., Degenhardt, L. & Teesson, M. (2004). Cannabis use and psychotic disorders: An update. Drug and Alcohol Review 23, 433-443.
510. Hall, W., Degenhardt, L., & Teesson, M. (2009). Understanding comorbidity between substance use, anxiety and affective disorders: broadening the research base. Addictive Behaviours 34(6-7), 526-530.
511. Hall, W. & Dolan, K. (1996). Is there a role for contact tracing in preventing HIV transmission among drug users? Editorial. Addiction 91, 917-919.
512. Hall, W. & Farrell, M. (1997). Comorbidity of mental disorders with substance misuse. British Journal of Psychiatry 171, 4-5.
513. Hall, W., Flaherty, B., & Homel, P. (1992). Public perceptions of the risks and benefits of alcohol use. Australian Journal of Public Health 16, 38-42.
514. Hall, W. & Hando, J. (1993). Illicit amphetamine use as a public health problem in Australia. Medical Journal of Australia 159, 643-644.
515. Hall, W. & Hando, J. (1994). Route of administration and adverse effects of amphetamine use among young adults in Sydney, Australia. Drug and Alcohol Review 13, 277-284.
516. Hall, W., Hando, J., Darke, S., & Ross, J. (1996). Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction 91, 81-87.
517. Hall, W. & Heather, N. (1991). Issue of statistical power in comparative evaluations of minimal and intensive controlled drinking interventions. Addictive Behaviours 16, 83-87.
518. Hall, W., Hunter, E., & Spargo, R. (1993). Alcohol-related problems among a population sample of Aboriginal drinkers in the Kimberley region of Western Australia. Addiction 88, 1091-1100.
519. Hall, W., Hunter, E.M., & Spargo, R. (1994). Alcohol use and incarceration in a police lockup among Aboriginals in the Kimberley Region of Western Australia. Australian and New Zealand Journal of Criminology 27, 57-73.
520. Hall, W., Kimber, J., & Lynskey, M. (2001). Breaking the deadlock over an Australian trial of injectable opioid maintenance. Medical Journal of Australia 176, 72-73.
521. Hall, W., Lynskey, M., & Degenhardt, L. (2000). Trends in opiate-related deaths in the United Kingdom and Australia, 1985-1995. Drug and Alcohol Dependence 57, 247-254. (abstract available)
522. Hall, W. & Mant, A. (1996). Harm reduction as a focus for research. Drug and Alcohol Review 15, 5-6.
523. Hall, W. & Mattick, R. (1997). Ultrarapid opiate detoxification. Medical Journal of Australia 176, 393-396.
524. Hall, W. & Mattick, R.P. (2000). Is ultra-rapid opioid detoxification a viable option in the treatment of opioid dependence? CNS Drugs 14, 251-255. (abstract available)
525. Hall, W. & Mattick, R. P. (2007). Clinical update: Codeine maintenance in opioid dependence. Lancet, 370, 550-552.
526. Hall, W., & Mattick, R. P. (2008). Oral substitution treatments for opioid dependence. Lancet, 371(9631), 2150-2151.
527. Hall, W., Mattick, R., Saunders, J.B., & Wodak, A. (1997). Rapid opiate detoxification treatment. (Editorial) Drug and Alcohol Review 16, 325-328.
528. Hall, W. & Nelson, J. (1996). Correlates of the perceived health risks of marijuana among Australian adults. Drug and Alcohol Review 15, 137-144.
529. Hall, W., Ross, J., Lynskey, M., Law, M., & Degenhardt, L. (2000). How many dependent heroin users are there in Australia? Medical Journal of Australia, 528-531.
530. Hall, W. & Sannibale, C. (1996). Are there two types of alcoholism? Lancet 348, 1258.
531. Hall, W., Saunders, J., Babor, T., Aasland, O.G., Amundsen, A., Hodgson, R., & Grant, M. (1993). The structure and correlates of alcohol dependence: WHO Collaborative Project on Early Detection of Person with Harmful Alcohol Consumption - III. Addiction 88, 1627-1636.
532. Hall, W. & Solowij, N. (1996). Steering a course between the Charybdis of credulity and the Scylla of scepticism. Addiction 91, 770-773.
533. Hall, W. & Solowij, N. (1997). Long-term cannabis use and mental health (Editorial). British Journal of Psychiatry 171, 107-108.
534. Hall, W. & Solowij, N. (1998). Adverse effects of cannabis. Lancet 352, 1611-1616.
535. Hall, W., Solowij, N., & Lemon, J. (1996). A Summary of "The Health and Psychological Effects of Cannabis". Addiction 91, 759-762.
536. Hall, W. & Swift, W. (2000). The THC content of cannabis in Australia: Evidence and implications. Australian and New Zealand Journal of Public Health 24, 503-508. (abstract available)
537. Hall, W., Teesson, M., Lynskey, M. & Degenhardt, L. (1999). The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: Findings from the National Survey of Mental Health and Well-Being. Addiction 94, 1541-1550.
538. Hall, W., Ward, J., Mattick, R.P. (1993). Methadone maintenance treatment in prisons: The New South Wales experience. Drug and Alcohol Review 12, 193-203. Also reprinted in Psychiatry, Psychology & Law, 1, 33-44 (1994).
539. Hall, W. & Wodak, A. (1999). Is naltrexone a cure for heroin dependence? (Editorial). Medical Journal of Australia 171, 9-10.
540. Hall, W. & Zador, D. (1997). The alcohol withdrawal syndrome. Lancet 349, 1897-1900.
541. Hall, W. & Zador, D. (2000) Challenge of reducing drug-related deaths. Lancet 356, 7.
542. Hando, J., Darke, S., O'Brien, S., Maher, L., & Hall, W. (1998). The development of an early warning system to detect trends in illicit drug use in Australia: The Illicit Drug Reporting System. Addiction Research 6, 97-113.
543. Hando, J., Flaherty, B., & Rutter, S. (1997). An Australian profile on the use of cocaine. Addiction 92, 173-182.
544. Hando, J. & Hall, W. (1994). HIV risk-taking behaviour among amphetamine users in Sydney, Australia. Addiction 89, 79-85.
545. Hando, J., Howard, J., & Zibbert, E. (1997). Risky drug practices and treatment needs of youth detained in New South Wales Juvenile Justice Centres. Drug and Alcohol Review 16, 137-145.
546. Hando, J., Topp, L., & Hall, W. (1997). Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug and Alcohol Dependence 46, 105-113.
547. Harvey, E., Shakeshaft, A., Hetherington, K., Sannibale, C., & Mattick, R.P. (2007). The efficacy of diversion and aftercare strategies for adult drug-involved offenders: A summary and methodological review of the outcome literature. Drug and Alcohol Review 26, 379-387.
548. Havard, A., Teesson, M., Darke, S., Ross, J. (2006). Depression among heroin users: 12 month outcomes from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse and Treatment 30, 355-362.
549. Havard, A., Shakeshaft, A., & Sanson-Fisher, R. (2008). Systematic review and meta-analyses of strategies targeting alcohol problems in emergency departments: Interventions reduce alcohol-related injuries. Addiction, 103, 368-376.
550. Hawkins, N., Sanson-Fisher, R., Shakeshaft, A., & Webb, G. (2009). Differences in licensee, police and public opinions regarding interventions to reduce alcohol-related harm associated with licensed premises. Australian and New Zealand Journal of Public Health 33(2), 160-166.
551. Hawkins, N. G., Shakeshaft, A., & Sanson-Fisher, R. W. (2006). A community-based attempt to reduce alcohol-related harms in rural New South Wales. Alcoholism-Clinical and Experimental Research, 30(9), 180A-180A.
552. Hawkins, N. G., Sanson-Fisher, R. W., Shakeshaft, A., D'Este, C., & Green, L. W. (2007). The multiple baseline design for evaluating population-based research. American Journal of Preventive Medicine, 33(2), 162-168.
553. Hayatbakhsh, M.R., Alati, R., Hutchinson, D., Jamrozik, K., Najman, J.M., Mamun, A.A., O’Callaghan, M., & Bor, W. (2007). Association of maternal smoking and alcohol consumption with young adults’ cannabis use: A prospective study. American Journal of Epidemiology 166, 592-598.
554. Hayward, L., Mant, A., Eyland, E.A., Hewitt, H., Pond, C.D., & Saunders, N.A. (1992). Neuropsychological functioning and sleep patterns in the elderly. Medical Journal of Australia 157, 51-52.
555. Heather, N. (1988). Lessons from a controlled evaluation of a general practice minimal intervention for problem drinking. Australian Drug and Alcohol Review 7, 317-328.
556. Heather, N. (1989). Psychology and brief interventions. British Journal of Addiction 84, 357-370.
557. Heather, N. (1989). Disulfiram treatment for alcoholism: Deserves re-examination. British Medical Journal 299, 471-472.
558. Heather, N. (1989). Problem drinking as a form of learned behaviour. A reply to Gorman. British Journal of Addiction 84, 847-848.
559. Heather, N. (1989). Problem drinking as a form of learned behaviour: A final rejoinder to Gorman and Edwards. British Journal of Addiction 85, 617-620.
560. Heather, N. (1990). DRAMS. A reply from Nick Heather. Drug and Alcohol Review 9, 290.
561. Heather, N. (1992). Why alcoholism is not a disease. Medical Journal of Australia 156, 212-215.
562. Heather, N. (1992). Comments on S. Peele, ‘Alcoholism, politics and bureaucracy: The consensus against controlled- drinking therapy in America’. Addictive Behaviours 17, 73-74.
563. Heather, N. (1992). Addictive disorders are essentially motivational problems Commentary on Davidson’s ‘Prochaska and DiClemente’s model of change: A case study’. British Journal of Addiction 87, 825-835.
564. Heather, N. & Bradley, B.P. (1990). Cue exposure as a practical treatment for addictive disorders: Why are we waiting? Addictive Behaviours 15, 335-337.
565. Heather, N. & Greeley, J. (1990). Cue exposure in the treatment of drug dependence: The potential of a new method for preventing relapse. Drug and Alcohol Review 9, 155-168.
566. Heather, N., Kissoon-Singh, J., & Fenton, G.W. (1990). Assisted natural recovery from alcohol problems: Effects of a self-help manual with and without supplementary telephone contact. British Journal of Addiction 85, 1177-1185.
567. Heather, N., & Mattick, R.P. (1994). The development of guidelines for drug and alcohol dependence treatment: Affecting policy and practice. Drug and Alcohol Review 13, 119-126.
568. Heather, N. & Richmond, R. (1991). Research into brief interventions for excessive drinkers and smokers. Journal of Drug Issues 22, 641-660.
569. Heather, N., Stallard, A., & Tebbutt, J. (1991). Importance of substance cues in relapse among heroin users: Comparison of two methods of investigation. Addictive Behaviours 16, 41-49.
570. Heather, N. & Tebbutt, J. (1989). Definitions of non-abstinent and abstinent categories in alcoholism treatment outcome classifications. Drug and Alcohol Dependence 24, 83-93.
571. Heather, N., Tebbutt, J., Mattick, R.P., & Zamir, R. (1993). Development of a scale for measuring impaired control over alcohol consumption. Journal of Studies on Alcohol 58, 700-709.
572. Henderson, S., Andrews, G., & Hall, W. (2000) Australia’s mental health: An overview of the general population survey. Australian and New Zealand Journal of Psychiatry 34, 197-205. (abstract available)
573. Henderson, N. & Huon, G. (2002). Negative affect and binge eating in overweight women. British Journal of Health Psychology 7, 77-87.
574. Hickman, M., Taylor, C., Chatterjee, A., Degenhardt, L., Frischer, M., Hay, G., Tilling, K., Weissing, L., Griffiths, P., & McKetin, R. (2004). Estimating the prevalence of problematic drug use: A review of methods and their application. Bulletin on Narcotics, vol LIV, Nos 1 and 2, 15-32.
575. Hines, S., Theodorou, S., Williamson, A., Fong, D., & Curry, K. (2008). Management of acute pain in methadone maintenance therapy in-patients. Drug and Alcohol Review, 27(5), 519-523.
576. Homel, P., Flaherty, B., Reilly, C., Hall, W., & Carless, J. (1990). The market position of cocaine among young Australian adults. British Journal of Addiction 85, 891-897.
577. Howard, J., Lennings, C. & Copeland, J. (2003). Suicidal behaviour in a young offender population. Crisis 24, 98-104.
578. Hughes, C. (2007). Evidence-based policy or policy-based evidence? The role of evidence in the development and implementation of the Illicit Drug Diversion Initiative. Drug and Alcohol Review 26, 363-368.
579. Humeniuk, R., Ali, R., McGregor, C., & Darke, S. (2003). Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. Addiction 98,413-418. (abstract available)
580. Hunter, E.M. (1991). The intercultural and socio-historical context of Aboriginal personal violence in remote Australia. Australian Psychologist 26, 89-98.
581. Hunter, E.M. (1991). Out of sight, out of mind – 1. Emergent patterns of self-harm among Aborigines of remote Australia. Social Science Medicine 33, 655-659.
582. Hunter, E.M. (1991). Out of sight, out of mind – 2. Social and historical contexts of self-harm behaviour among Aborigines of remote Australia. Social Science Medicine 33, 661-671.
583. Hunter, E., Hall, W., & Spargo, R. (1992). Patterns of alcohol consumption in the Kimberley Aboriginal population. Medical Journal of Australia 156, 764-768.
584. Hutchinson, D. M., Alati, R., Najman, J. M., Mattick, R. P., Bor, W., O'Callaghan, M., et al. (2008). Maternal attitudes in pregnancy predict drinking initiation in adolescence. Australian and New Zealand Journal of Psychiatry, 42(4), 324-334.
585. Hutchinson, D. & Rapee, R. (2007). Do friends share similar body image and eating problems? The role of social networks and peer influences in early adolescence. Behaviour Research and Therapy 45, 1557-1577.
586. Indig, D., Copeland, J., & Conigrave, K. M. (2008). Young people who attend specialist alcohol treatment: Who are they and do they need special treatment ? Australian and New Zealand Journal of Public Health, 32(4), 336-340.
587. Indig, D., Eyeson-Annan, M., Copeland, J., & Conigrave, K.M. (2007). The effects of alcohol consumption, psychological distress and smoking status on emergency department presentations in New South Wales, Australia. BMC Public Health 2, 46-55.
588. Islam, M. M., & Conigrave, K. M. (2007). Increasing prevalence of HIV, and persistent high-risk behaviours among drug users in Bangladesh: Need for a comprehensive harm reduction programme. Drug and Alcohol Review, 26(4), 445-454.
589. Islam, M. M., Stern, T., Conigrave, K. M., & Wodak, A. (2008). Client satisfaction and risk behaviours of the users of syringe dispensing machines: A pilot study. Drug and Alcohol Review, 27(1), 13-19.
590. Issakidis, C., Sanderson, K., Teesson, M., Johnston, S. & Buhrich, N. (1999). Intensive case management in Australia: A randomized controlled trial. Acta Psychiatrica Scandinavica 99, 360-367.
591. Issakidis, C. & Teesson, M. (1999). Measurement of need for care: A trial of the Camberwell Assessment of Need (CAN) and the HoNOS. Australian and New Zealand Journal of Psychiatry 33, 754-760.
592. Jauncey, M., Taylor, L. & Degenhardt, L. (2005). The definition of opioid-related deaths in Australia: Implications for surveillance and policy. Drug and Alcohol Review 24, 401-409. (abstract available)
593. Jarvis, T. (1992). Implications of gender for alcohol treatment research: A quantitative and qualitative review. British Journal of Addiction 87, 1249-1261. (abstract available)
594. Jarvis, T.J. & Copeland, J. (1997). Child sexual abuse as a predictor of psychiatric co-morbidity and its implications for drug and alcohol treatment. Drug and Alcohol Dependence 49, 61-70.
595. Jarvis, T.J., Copeland, J. & Walton, L. (1998). Exploring the nature of the relationship between child sexual abuse and substance use among women. Addiction 93, 865-875.
596. Jauncey, M., Taylor, L. & Degenhardt, L. (2005). The definition of opioid-related deaths in Australia: Implications for surveillance and policy. Drug and Alcohol Review 24, 401-409.
597. Johnson, B.D., Dunlap, E., & Maher, L. (1998). Nurturing for careers in drug abuse and crime: Conduct norms for children and youth in crack-abusing households. Substance Use and Misuse 33, 1515-1550.
598. Johnston, J., Barratt, M. J., Fry, C. L., Kinner, S., Stoove, M., Degenhardt, L., et al. (2006). A survey of regular ecstasy users' knowledge and practices around determining pill content and purity: Implications for policy and practice. International Journal of Drug Policy, 17(6), 464-472.
599. Johnston, S., Salkeld, G., Sanderson, K., Issakidis, C., Teesson, M., & Buhrich, N. (1998). Intensive case management: A cost-effective analysis. Australian and New Zealand Journal of Psychiatry 32, 551-559.
600. Jones, C., Donnelly, N., Swift, W., & Weatherburn, D. (2006). Preventing cannabis users from driving under the influence of cannabis. Accident Analysis and Prevention 38, 854-861.
601. Jones, C., Swift, W., Donnelly, N., & Weatherburn, D. (2007). Correlates of driving under the influence of cannabis. Drug and Alcohol Dependence 88, 83-86.
602. Kahn, M.W., Hunter, E, Heather, N., & Tebbutt, J. (1991). Australian Aborigines and alcohol: A review. Drug and Alcohol Review 10, 351-367.
603. Kavanagh, D.J., Baker, A. & Teesson, M. (2004). Special Section--Co-morbidity of mental disorders and substance misuse Introduction. Drug and Alcohol Review 23, 405-406.
604. Kaye, S. & Darke, S. (2000). Comparison of the harms associated with the injection of heroin and amphetamines. Drug and Alcohol Dependence 58, 189-195.
605. Kaye, S. & Darke, S. (2002). Determining a diagnostic cut-off on the Severity of Dependence Scale (SDS) for cocaine dependence. Addiction 97, 727-731. (abstract available)
606. Kaye, S. & Darke, S. (2004). Injecting and non-injecting cocaine use in Sydney, Australia: Physical and psychological morbidity. Drug and Alcohol Review 23, 391-398.
607. Kaye, S. & Darke, S. (2004). Non-fatal cocaine overdose among injecting and non-injecting cocaine users in Sydney, Australia. Addiction 99, 1315-1322.
608. Kaye, S., Darke, S., & & Duflou, J. (2009). Methylenedioxymethamphetamine (MDMA) - related fatalities in Australia: Demographics, circumstances, toxicology and major organ pathology. Drug and Alcohol Dependence, 104, 254-261.
609. Kaye, S., Darke, S., Duflou, J., & McKetin, R. (2008). Methamphetamine-related fatalities in Australia: Demographics, circumstances, toxicology and major organ pathology. Addiction, 103(8), 1353-1360.
610. Kaye, S., Darke, S., & Finlay-Jones, R. (1998). The onset of heroin use and criminal behaviour: Does order make a difference? Drug and Alcohol Dependence 53, 79-86.
611. Kaye, S., McKetin, R., Duflou J. & Darke, S. (2007). Methamphetamine and cardiovascular pathology: A review of the evidence. Addiction 102, 1204-1211.
612. Kay-Lambkin, F. J. (2008). Technology and innovation in the psychosocial treatment of methamphetamine use, risk and dependence. Drug and Alcohol Review, 27(3), 318-325.
613. Kehoe, L., Hall, W., & Mant, A. (1992). Estimating the number of dependent heroin users in the Eastern Area Health Service of Sydney. Australian Journal of Public Health 16, 232-237.
614. Kelaher, M., Darke, S., Hall, W., & Flaherty, B. (1996). Characteristics of admissions to residential drug treatment agencies in New South Wales, 1988-1992: II. Alcohol problems. Drug and Alcohol Review 15, 133-136.
615. Kelly, E., Darke, S. & Ross, J. (2004). A review of drug use and driving: Epidemiology, impairment, risk factors and risk perceptions. Drug and Alcohol Review 23, 311-317.
616. Kimber, J. & Dolan, K. (2001) A view from Australia (book review). International Journal of Drug Policy 12, 203.
617. Kimber, J., & Dolan, K. (2007). Shooting gallery operation in the context of establishing a medically supervised injecting center: Sydney, Australia. Journal of Urban Health-Bulletin of the New York Academy of Medicine, 84, 255-266.
618. Kimber, J., Dolan, K. & Wodak, A. (2005). Survey of drug consumption rooms: Service delivery and perceived public health and amenity impact. Drug Alcohol Review 24, 21-24.
619. Kimber, J., Dolan, K., van Beek, I., Hedrich, D., & Zurhold, H. (2003). Drug consumption facilities: An update since 2000. Drug and Alcohol Review 22, 227-233.
620. Kimber, J., Hickman, M., Degenhardt, L., Coulson, T., & van Beek, I. (2008). Estimating the size and dynamics of an injecting drug user population and implications for health service coverage: comparison of indirect prevalence estimation methods. Addiction, 103(10), 1604-1613.
621. Kimber, J., MacDonald, M., van Beek, I., Kaldor, J., Weatherburn, D., Lapsley, H., & Mattick, R.P. (2003). The Sydney Medically Supervised Injecting Centre: Client characteristics and predictors of frequent attendance during the first 12 months of operation. Journal of Drug Issues (Summer), 639-648. (abstract available)
622. Kinner, S. & Degenhardt, L. (2006). Reflections on the development and implementation of an early warning system for ecstasy and related drug markets in Australia. Drug and Alcohol Review 25, 445-449.
623. Kinner, S. A., & Degenhardt, L. (2008). Crystal methamphetamine smoking among regular ecstasy users in Australia: Increases in use and associations with harm. Drug and Alcohol Review, 27(3), 292-300.
624. Kinner, S. A., George, J., Campbell, G., & Degenhardt, L. (2009). Crime, drugs and distress: patterns of drug use and harm among criminally involved injecting drug users in Australia. Australian and New Zealand Journal of Public Health 33(3), 223-227.
625. Lamb, C. E. F., Boers, M., Owens, A., Copeland, J., & Sultana, T. (2008). Exploring experiences and attitudes about health care complaints among pregnant women, mothers and staff at an Opioid Treatment Service. Australian Health Review, 32(1), 66-75.
626. Large, M., Farooq, S., Nielssen, O., & Slade, T. (2008). Relationship between gross domestic product and duration of untreated psychosis in low- and middle-income countries. British Journal of Psychiatry, 193(4), 272-278.
627. Larney, S., & Dolan, K. (2008). An exploratory study of needlestick injuries among Australian prison officers. International Journal of Prisoner Health, 4(3), 164-168.
628. Larney, S., & Dolan, K. (2008). Increased access to opioid substitution treatment in prisons is needed to ensure equivalence of care [2]. Australian and New Zealand Journal of Public Health, 32(1), 86-87.
629. Larney, S., & Dolan, K. (2009). A literature review of international implementation of opioid substitution treatment in prisons: Equivalence of care. European Addiction Research 15(2), 107-112.
630. Law, M.G., Degenhardt, L., & McKetin, R. (2006). Methods estimating the prevalence of problem drug use (Response). International Journal of Drug Policy 17, 154-158.
631. Law, M.G., Dore, G.J., Bath, N., Thompson, S., Crofts, N., Dolan, K., Giles, W., Gow, P., Kaldor, J., Loveday, S., Powell, E., Spencer, J., & Wodak, A. (2003). Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. International Journal of Epidemiology 32, 717-724. (abstract available)
632. Law, M.G., Lynskey, M., Ross, J., & Hall, W. (2001) Back-projection estimates of the number of dependent heroin users. Addiction 96, 433-443. (abstract available)
633. Lawrinson, P., Copeland, J. & Indig, D. (2005). Development and validation of a brief instrument for routine outcome monitoring in opioid maintenance pharmacotherapy. Drug and Alcohol Dependence 80, 125-134.
634. Lawrinson, P., Copeland, J. & Indig, D. (2006). Regional differences in patterns of drug use, HIV risk taking and psycho-social health among those entering opioid maintenance pharmacotherapies in NSW 2000-2002. Drug and Alcohol Dependence 82 Suppl 1, S95-S102.
635. Lawrinson, P., Copeland, J., Gerber, S., & Gilmour, S. (2007). Determining a cut-off on the Severity of Dependence Scale (SDS) for alcohol dependence. Addictive Behaviors, 32, 1474-1479.
636. Lee, A., Tan, S., Lim, D., Winslow, R.M., Wong, K.E., Allen. J., Hall, W., & Parker, G. (2001). Naltrexone in the treatment of male alcoholics - an effectiveness study in Singapore. Drug and Alcohol Review 20, 193-199.
637. Lee, K. S. K., Conigrave, K. M., Clough, A. R., Wallace, C., Silins, E., & Rawles, J. (2008). Evaluation of a community-driven preventive youth initiative in Arnhem Land, Northern Territory, Australia. Drug and Alcohol Review, 27(1), 75-82.
638. Lemon, J. (2008). Residual effects of alcohol on skilled performance. Alcohol and Alcoholism, 43(4), 498-498.
639. Lemon, J., Chesher, G., Fox, A., Greeley, J., & Nabke, C. (1993). Investigation of the “hangover” effects of an acute dose of alcohol on psychomotor performance. Alcoholism: Clinical and Experimental Research 17, 665-668.
640. Lemon, J., & Tyagi, A. (2009). The Fan Plot: A technique for displaying relative quantities and differences. Statistical Computing and Graphics Newsletter, 20(1): 8-10.
641. Lenné, M., Lintzeris, N., Breen, C., Harris, S., Hawken, L., Mattick, R., & Ritter, A. (2001). Withdrawal from methadone maintenance treatment: Prognosis and participant perspectives. Australian and New Zealand Journal of Public Health 25, 121-125.
642. Lennings, C., Copeland, J. & Howard, J. (2003). Substance use patterns of young offenders and violent crime. Aggressive Behaviour 29, 414-422.
643. Large, M., Farooq, S., Nielssen, O., & Slade, T. (2008). Relationship between gross domestic product and duration of untreated psychosis in low- and middle-income countries. British Journal of Psychiatry, 193(4), 272-278.
644. Lind, B., Chen, S. L., Weatherburn, D., & Mattick, R. (2005). The effectiveness of methadone maintenance treatment in controlling crime - An Australian aggregate-level analysis. British Journal of Criminology, 45(2), 201-211.
645. Loxley, W., Carruthers, S., Wodak, A., Crofts, N., Dolan, K., & Gaughwin, M. (1995). Patterns of infection. National AIDS Bulletin, 9 , 26-27.
646. Lynskey, M. (1998). The comorbidity of alcohol dependence and affective disorders: Treatment implications. Drug and Alcohol Dependence 52, 201-209.
647. Lynskey, M., Coffey, C., Degenhardt, L., Carlin, J.B., & Patton, G. (2003). A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction 98, 685-692.
648. Lynskey M.L., Day, C. & Hall, W. (2003) Alcohol and other drug use disorders among older aged people. Drug and Alcohol Review 22, 125-133.
649. Lynskey, M., Degenhardt, L. & Hall, W. (2000). Cohort trends in youth suicide in Australia 1964-1997. Australian and New Zealand Journal of Psychiatry 34, 408-412.
650. Lynskey, M. & Hall, W. (1998). Jurisdictional trends in opioid overdose deaths, 1988-96. Australian and New Zealand Journal of Public Health 22, 802-807.
651. Lynskey, M. & Hall, W. (1998). Cohort trends in age of initiation to heroin use. Drug and Alcohol Review 17, 289-298.
652. Lynskey, M. & Hall, W. (1999). A reply to Caplehorn. Drug and Alcohol Review 18, 488.
653. Lynskey, M. & Hall, W. (2000). The effects of adolescent cannabis use on educational attainment: A review. Addiction 95, 1621-1630. (abstract available)
654. Lynskey, M. & Hall, W. (2001). Attention deficit hyperactivity disorder and substance use disorders: Is there a causal link? Addiction 96, 815-822.
655. Lynskey, M., Heath, A.C., Nelson, E.C., Bucholz, K.K., Maddem, P.A.F., Slutske, W.S., Statham, D.J., & Martin, N.G. (2002). Genetic and environmental contributions to cannabis dependence in a national young adult twin sample. Psychological Medicine 32, 195-207.
656. Lynskey, M., White, V., Hill, D., Letcher, T. & Hall, W. (1999). Prevalence of illicit drug use among youth: Results from the Australian School Students’ Alcohol and Drugs Survey. Australian and New Zealand Journal of Public Health 23, 1519-524.
657. MacDonald, M. & Wodak, A. (1999). Preventing transmission of hepatitis C. Australian Family Physician 28 (suppl 2), 1-5.
658. MacDonald, M., Wodak, A., Ali, R., Crofts, N., Cunningham, P., Dolan, K., Kelaher, M., Loxley, W., van Beek, I., & Kaldor, J. (1997). HIV prevalence and risk behaviour in needle exchange attenders - a national study. Medical Journal of Australia 166, 237 - 240.
659. MacDonald, M.A., Wodak, A.D., Dolan, K.A., van Beek, I., Cunningham, P.H., & Kaldor, J.M. (2000). Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Medical Journal of Australia 172, 57-61. (abstract available)
660. Maher, L., & Daly, K. (1996). Women in the street-level drug economy: continuity or change? Criminology 34, 465-491.
661. Maher, L. & Dixon, D. (1999). Policing and public health: Law enforcement and harm minimization in a street-level drug market. British Journal of Criminology 39, 488-512.
662. Maher, L. & Johnson, B.D. (1999). Heroin, HIV and harm in New York and Sydney. Medical Journal of Australia 171, 163-165.
663. Maher, L., Swift, W., & Dawson, M. (2001). Heroin purity and composition in Sydney. Drug and Alcohol Review 20, 439-448. (abstract available)
664. Maloney, E., Degenhardt, L., Darke, S., Mattick, R.P., & Nelson, E. (2007). Suicidal behaviour and associated risk factors among opioid-dependent individuals: A case–control study. Addiction 102, 1933-1941.
665. Maloney, E., Degenhardt, L., Darke, S., & Nelson, E. C. (2009). Are non-fatal opioid overdoses misclassified suicide attempts? Comparing the associated correlates. Addictive Behaviours 39(9), 723-729.
666. Maloney, E., Degenhardt, L., Darke, S., & Nelson, E. C. (2009). Impulsivity and borderline personality as risk factors for suicide attempts among opioid-dependent individuals. Psychiatry Research 169, 16-21. (abstract available)
667. Mant, A. (1991). Are your patients oversedated? And if so, is it worth worrying about? Patient Management 16, 15-17.
668. Mant, A. (1993). Insomnia: Evaluate first before considering hypnotics. Drug and Therapeutic Perspectives 2, 7.
669. Mant, A., De Burgh, S., Mattick, R.P., Donnelly, N., & Hall, W. (1995). Insomnia in general practice: Results from the NSW general practice survey 1991-1992. Australian Family Physician 25, S15-S18.
670. Mant, A., Kehoe, L., Eyland, E.A., Purcell, C., Pond, C.D., Hewitt, H., & Saunders, N.A. (1990). Use of medications by the elderly. Australian Family Physician 9, 511.
671. Mant, A., Mattick, R.P., DeBurgh, S., Donnelly, N., & Hall, W. (1994). Clinical and non-clinical determinants of benzodiazepine prescribing in general practice: Dispelling some myths. Family Practice 12, 37-43.
672. Mant, A. & Saunders, N.A. (1990). Polypharmacy in the elderly (letter to the editor). Medical Journal of Australia 152, 612.
673. Mant, A., Whicker, S.D., & Kwok, Y.S. (1992). Over-the-counter self medication: The issues. Drugs and Aging 2, 257-261.
674. Marley, J., & Mant, A. (1993). Post marketing surveillance – traps for the unwary. Australian Family Physician 22,1009-1013.
675. Martin, G., & Copeland, J. (2008). The adolescent cannabis check-up: Randomized trial of a brief intervention for young cannabis users. Journal of Substance Abuse Treatment, 34(4), 407-414.
676. Martin, G., Copeland, J., Gates, P., & Gilmour, S. (2006). The Severity of Dependence Scale (SDS) in an adolescent population of cannabis users: Reliability, validity and diagnostic cut-off. Drug and Alcohol Dependence 83, 90-93.
677. Martin, G., Copeland, J., Gilmour, S., Gates, P. & Swift, W. (2006). The Adolescent Cannabis Problems Questionnaire (CPQ-A): Psychometric properties.Addictive Behaviors 31, 2238-2248.
678. Martin, G., Copeland, J. & Swift, W. (2005). The Adolescent Cannabis Check-up: Feasibility of a brief intervention for young cannabis users. Journal of Substance Abuse Treatment 29, 207-213.
679. Martin, B.R. & Hall, W. (1997/1998). The health effects of cannabis: Key issues of policy relevance. Bulletin on Narcotics 49-50, 85-116.
680. Matthew, A., Bruno, R., Johnson, J., Black, E., Degenhardt, L., & Dunn, M. (2009). Factors associated with driving under the influence of alcohol and drugs among an Australian sample of regular ecstasy users. Drug and Alcohol Dependence 100(1-2), 24-31.
681. Mattick, R.P. (1994). Dual diagnosis: Evaluation, treatment, training, and program evaluation (book review). Addiction 90, 139-140.
682. Mattick, R.P. (1994). Dual diagnosis: Evaluation, treatment, training, and program evaluation (book review). Drug and Alcohol Review 13, 349-352.
683. Mattick, R.P. (1995). Residential treatment for alcohol dependent patients? (Letter to the editor). Drug and Alcohol Review 14, 134-135.
684. Mattick, R.P. (1995). Addiction: From biology to drug policy. (book review). Behaviour Change.
685. Mattick, R.P. (1996). The stop smoking workbook: Your guide to healthy quitting (book review). Addiction 92, 223.
686. Mattick, R.P. (1996). How to have a high success rate in treatment: Commentary. Addiction 92, 484-485.
687. Mattick, R.P. (1997). Single and Rohl on "Mapping the future". Drug and Alcohol Review 17, 5-8.
688. Mattick, R.P. (1999). Cognitive-behavioural strategies to prevent relapse. Medicine 27, 20-21.
689. Mattick, R.P., Ali, R., Auriacombe, M., Davoli, M., Faggiano, F., Farrell, M., Ferri, M., & Ling, W. (2001). Cochrane Drugs and Alcohol Group: The development of systematic reviews of treatment outcome. Alcohol & Alcoholism 36, 109-111.
690. Mattick, R.P., Ali, R., White, J.M., O’Brien, S., Wolk, S., & Danz, C. (2003). Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 98,441-452. (abstract available)
691. Mattick, R.P., Andrews, G., Hadzi-Pavlovic, D., & Christensen, H. (1990). Treatment of panic and agoraphobia: An integrative review. Journal of Nervous and Mental Disease 178, 567-576.
692. Mattick, R.P., Baillie, A. J., Digiusto, E., Gourlay, S., Richmond, R., & Stanton, H. (1994). A summary of the recommendations for smoking cessation interventions: The quality assurance in the treatment of drug dependence project. Drug and Alcohol Review 13, 171-178.
693. Mattick, R.P. & Clarke, J.C. (1998). Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behaviour Research and Therapy 36, 455-470.
694. Mattick, R.P. & Darke, S. (1995). Drug replacement treatments: Is amphetamine substitution a horse of a different colour? Drug and Alcohol Review14, 389-394.
695. Mattick, R.P. & Degenhardt, L. (2003). Methadone-related and heroin-related deaths among opiate users: Methadone helps saves lives (Editorial). Addiction 98, 387-388.
696. Mattick, R.P., Farrell, M., Hall, W., Ward, J., Gossop, M., & Strang, J. (1995). Methadone maintenance treatment: A reply. British Medical Journal 310, 1408.
697. Mattick, R.P. & Grenyer, B.F. (1990). Quality assurance in drug and alcohol treatment: The development of standards for treatment content. Drug and Alcohol Review 9, 75-79.
698. Mattick, R.P. & Hall, W. (1994). A summary of the recommendations for the management of opioid problems: The quality assurance in the treatment of drug dependence project. Drug and Alcohol Review 13, 319-326.
699. Mattick, R.P. & Hall, W. (1996). Are detoxification programmes effective? Lancet 347, 97-100.
700. Mattick, R.P., & Heather, N. (1993). Developments in cognitive and behavioural approaches to substance misuse. Current Opinion in Psychiatry 6, 424-429.
701. Mattick, R.P. & Jarvis, T. J. (1994). Inpatient setting and long duration for the treatment of alcohol dependence? Outpatient care is as good. Drug and Alcohol Review 13, 127-136.
702. Mattick, R.P. & Jarvis, T. J. (1994). Brief or minimal intervention for 'alcoholics': The evidence suggests otherwise. Drug and Alcohol Review 13, 137-144.
703. Mattick, R.P. & Jarvis, T. J. (1994). A summary of the recommendations for the management of alcohol problems: The quality assurance in the treatment of drug dependence project. Drug and Alcohol Review 13, 145-156.
704. Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews(2).
705. Mattick, R.P. & McLaren, J. (2006). Cannabis and psychosis put in perspective. The Canadian Journal of Psychiatry 51, 554-555.
706. Mattick, R.P. & Newman, C. (1991). Social phobia and avoidant personality disorder. International Review of Psychiatry 3, 163-173.
707. Mattick, R.P. & Peters, L. (1988). Treatment of severe social phobia: Effects of guided exposure with and without cognitive restructuring. Journal of Consulting and Clinical Psychology 56, 251-260.
708. Mattick, R.P., Peters, L., & Clarke, J. C. (1989). Exposure and cognitive restructuring for social phobia: A controlled study. Behavior Therapy 20, 3-23.
709. Mattick, R.P. & Ward, J. (1992). Drug and alcohol treatment research, policy and practice: An Australian perspective. Journal of Drug Issues 22, 625-640.
710. McBride, O., Teesson, M., Slade, T., Hains, D., Degenhardt, L., & Baillie, A. (2009). Further evidence of differences in substance use and dependence between Australia and the United States. Drug and Alcohol Dependence 100(3), 258-264.
711. McCambridge, J., Hunt, N., Winstock, A., & Mitcheson, L. (2005). Has there been a decline in the prevalence of cannabis use among British nightclubbers? Five-year survey data. Drugs: Education, Prevention and Policy 12, 167-169.
712. McCambridge, J., Mitcheson, L., Hunt, N., & Winstock, A., (2006). The rise of Viagra among British illicit drug users: 5-year survey data. Drug and Alcohol Review 25, 111-114.
713. McCambridge, J., Winstock, A., Hunt, N., & Mitcheson, L. (2007). 5-year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. European Addiction Research13, 57-64.
714. McEvoy, P. M., & Shand, F. (2008). The effect of comorbid substance use disorders on treatment outcome for anxiety disorders. Journal of Anxiety Disorders, 22(6), 1087-1098.
715. McGregor, C., Ali, R., Christie, P., & Darke, S. (2001). Overdose among heroin users: Evaluation of an intervention in South Australia. Addiction Research and Theory, 9, 481-501. (abstract available
716. McGregor, C., Ali, R., Lokan, R., Christie, P., & Darke, S. (2002). Accidental fatalities among heroin users in South Australia, 1994-1997: Toxicological findings and circumstances of death. Addiction Research and Theory 10, 335-346. (abstract available)
717. McGregor, C., Darke, S., Christie, P., & Ali, R. (1998). Experience of non-fatal overdose among heroin users in Adelaide: Circumstances and risk perception. Addiction 93, 701-711.
718. McKetin, R. (1999). Use of RAM to monitor illicit drug use in developed countries: Can rapid assessment result in a rapid response? (Comment on Stimson et al). Drug and Alcohol Review 18, 333-335.
719. McKetin, R. (2008). Methamphetamine precursor regulation: Are we controlling or diverting the drug problem? Addiction, 103(4), 521-523.
720. McKetin, R. (2009). The Holy Grail of Supply control have we fund the evidence? Addiction 104(3), 455-456.
721. McKetin, R. & Griffiths, P. (2003). Developing a global perspective on drug information systems (Editorial). Drug and Alcohol Review 22, 387-389.
722. McKetin, R. & Kelly, E. (2007). Socio-demographic factors associated with methamphetamine treatment contact among dependent methamphetamine users in Sydney, Australia. Drug and Alcohol Review 26, 161-168.
723. McKetin, R., Kelly, E. & Indig, D. (2005). Characteristics of treatment provided for amphetamine use in New South Wales, Australia. Drug and Alcohol Review 24, 433-436. (abstract available)
724. McKetin, R., Kelly, E. & McLaren, J. (2006). The relationship between crystalline methamphetamine use and methamphetamine dependence. Drug and Alcohol Dependence 85, 198-204.
725. McKetin, R., Kelly, E., McLaren, J., & Proudfoot, H. (2008). Impaired physical health among methamphetamine users in comparison with the general population: The role of methamphetamine dependence and opioid use. Drug and Alcohol Review, 27(5), 482-489.
726. McKetin, R., Kozel, N., Douglas, J., Ali, R., Vicknasingam, B., Lund, J., et al. (2008). The rise of methamphetamine in Southeast and East Asia. Drug and Alcohol Review, 27(3), 220-228.
727. McKetin, R. & Mattick, R. (1997). Attention and memory in illicit amphetamine users. Drug and Alcohol Dependence 48, 235-242.
728. McKetin, R. & Mattick, R.P. (1998). Attention and memory in illicit amphetamine users: Comparison with non-drug-using controls. Drug and Alcohol Dependence 50, 181-184.
729. McKetin, R., McLaren, J., Lubman, D., & Hides, L. (2006). The prevalence of psychotic symptoms among methamphetamine users. Addiction 101, 1473-1478.
730. McKetin, R., McLaren, J., Lubman, D. I., & Hides, L. (2008). Hostility among methamphetamine users experiencing psychotic symptoms. American Journal on Addictions, 17(3), 235-240.
731. McKetin, R., Ross, J., Kelly, E., Baker, A., Lee, N., Lubman, D. I., et al. (2008). Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants. Drug and Alcohol Review, 27(3), 277-285.
732. McKetin, R. & Solowij, N. (1999). Event-related potential indices of auditory selective attention in dependent amphetamine users. Biological Psychiatry 45, 1488-1497. (abstract available)
733. McKetin, R., Ward, P.B., Catts, S.V., Mattick, R.P. & Bell, J. (1999). Changes in auditory selective attention and event-related potentials following oral administration of D-amphetamine in humans. Neuropsychopharmacology 21, 380-390.
734. McLaren, J., Swift, W., Dillon, P., & Allsop, S. (2008). Cannabis potency and contamination: A review of the literature. Addiction, 103(7), 1100-1109.
735. McLachlan, C., Crofts, N., Wodak, A., & Crowe, S. (1993). The effects of methadone on immune function in injecting drug users: A review. Addiction 88, 257-263.
736. McManus, P., Donnelly, N., Henry, D., Hall, W., Primrose, J., & Lindner, J. (1996). Prescription drug utilization following patient co-payment changes in Australia Pharmacoepidemiology and Drug Safety 5, 385 -392.
737. McPherson, M. & Spooner, C. (2004). Police contribution to illicit drug harm minimisation. Australian Police Journal September, 146-149.
738. Miller, P., & Degenhardt, L. (2009). The Global Diversion of Pharmaceutical Drugs series. Addiction 104(3), 333-334.
739. Miller, W.R. (1989). Raiding the lost ark: Do we need new models to study behaviour change in spiritual contexts? Spiritual and Religious Issues in Behaviour Change 4, 6-15.
740. Miller, W.R. (1990). Spiritually: The silent dimension in addictions research. Drug and Alcohol Review 9, 259-266.
741. Miller, W.R., Heather, N., & Hall, W. (1991). Calculating standard drink units: International comparisons. British Journal of Addictions 86, 43-47.
742. Miller, W.R. & Page, A.C. (1991). Warm turkey: Other routes to abstinence. Journal on Substance Abuse Treatment 8, 227-232.
743. Mills, K. L., Hodge, W., Johansson, K., & Conigrave, K. M. (2008). An outcome evaluation of the New South Wales Sober Driver Programme: A remedial programme for recidivist drink drivers. Drug and Alcohol Review, 27, 65-74.
744. Mills, K.L., Lynskey, M., Teesson, M., Ross, J., & Darke, S. (2005). Post-traumatic stress disorder among people with heroin dependence in the Australian treatment outcome study (ATOS): Prevalence and correlates. Drug and Alcohol Dependence 77, 243-249.
745. Mills, K. L., Teesson, M., Darke, S., Ross, J., & Lynskey, M. (2004). Young people with heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment 27, 67-73.
746. Mills, K., Teesson, M., Darke, S., & Ross, J. (2007). Reliability of self-reported trauma exposure among people with heroin dependence: A longitudinal investigation. Journal of Traumatic Stress, 20(3), 313-323.
747. Mills, K., Teesson, M., Ross, J. & Darke, S. (2007). The impact of post-traumatic stress disorder on treatment outcomes for heroin dependence. Addiction 102, 447-454.
748. Mills, K. L., Teesson, M., Ross, J., & Darke, S. (2008). Predictors of trauma and PTSD among heroin users: A prospective longitudinal investigation. Journal of Drug Issues, 38(2), 585-599.
749. Mills, K.L., Teesson, M., Ross, J., Darke, S., & Shanahan, M.A. (2005) The costs and outcomes of treatment for opioid dependence associated with Posttraumatic Stress Disorder. Psychiatric Services 56, 940-945.
750. Mills, K., Teesson, M., Ross, J., & Peters, L. (2006). Trauma, PTSD, and substance use disorders: Findings from the Australian National Survey of Mental Health and Well-Being. The American Journal of Psychiatry 163, 652-658.
751. Mitchell, P. & Mant, A. (1991). Insomnia Update. Medical Journal of Australia 154, 193-194.
752. Mitcheson, L., McCambridge, J., Byrne, A., Hunt, N., & Winstock, A. (2008). Sexual health risk among dance drug users: Cross-sectional comparisons with nationally representative data. International Journal of Drug Policy, 19(4), 304-310.
753. Moore, T.J., Ritter, A. & Caulkins, J.P. (2007). The costs and consequences of three policy options for reducing heroin dependency. Drug and Alcohol Review 26, 369-378.
754. Morlet, A., Darke, S., Guinan, J.J., Wolk, J., & Gold, J. (1990). Intravenous drug users who present to the Albion Street (AIDS) Centre for diagnosis and management of human immunodeficiency virus infection. Medical Journal of Australia 152, 78-80.
755. Newton, N. C., Andrews, G., Teesson, M., & Vogl, L. E. (2009). Delivering prevention for alcohol and cannabis using the internet: a cluster randomised controlled trial. Preventive Medicine 48(6), 579-584.
756. Newton, N. C., Vogl, L., Teesson, M., & Andrews, G. (2009). CLIMATE Schools: alcohol module: cross-validation of a school-based prevention programme for alcohol misuse. Australian and New Zealand Journal of Psychiatry 43(3), 201-207.
757. O'Brien, S., Day, C., Black, E., & Dolan, K. (2008). Injecting drug users' understanding of hepatitis C. Addictive Behaviors, 33, 1602-1605.
758. O’Brien, S., Mattick, R.P., White, J., Breen, C., Kimber, J., Ritter, A., Lintzeris, N., & the NEPOD Research Group. (2006). Maintenance pharmacotherapy for opioid dependence and SF-36 health status: A comparison with general population norms and other chronic disorders. Addictive Disorders & Their Treatment 5, 155-164.
759. O’Callaghan, F., Reid, A. & Copeland, J. (2006). Risk perception and cannabis use among a sample of young adults. Journal of Substance Use 11, 129-136.
760. O’Sullivan, B., Levy, M.H., Dolan, K.A., Post, J.J., Barton, S.G., Dwyer, D.G., Kaldor, J.M., & Grulich, A.E. (2003). Hepatitis C transmission and HIV post-exposure prophylaxis after needle- and syringe-sharing in Australian prisons. Medical Journal of Australia 178, 546-549.
761. Patton, G., Coffey, C., Carlin, J.B., Degenhardt, L., Lynskey, M., & Hall, W. (2002). Cannabis use and mental health in young people: Cohort study. British Medical Journal 325, 1195-1198.
762. Perdices, M., Dunbar, N., Grunseit, A., Hall, W., & Cooper, D. (1992). Anxiety, depression and HIV related symptomatology across the spectrum of HIV disease. Australian and New Zealand Journal of Psychiatry 26, 560-566.
763. Peters, R. (1997). Muscle bound. Australian Leisure Management, 28-29.
764. Peters, R., Copeland, J. & Dillon, P. (1999). Anabolic-androgenic steroid use: User characteristics, motivations and deterrents. Psychology of Addictive Behaviours 13, 232-242.
765. Post, J.J., Dolan, K.A., Whybin, L.R., Carter, I.W.J., Haber, P.S., & Lloyd, A.R. (2001). Acute hepatitis C virus infection on an Australian prison inmate: Tattooing as a possible transmission route. Medical Journal of Australia 174, 183-184.
766. Post, J., Pan, Y., Freeman, A., Harvey, C., White, P., Palladinetti, P., Haber, P., Marinos, G., Levy, M., Dolan, K., French, R., Lloyd, A., Rawlinson, W., & the Hepatitis C Incidence and Transmission in Prison Study (HITS) Group (2004). Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the Hepatitis C Incidence and Transmission in Prisons Study Cohort. Journal of Infectious Diseases 189, 1846-55.
767. Prescott, J. (1988). Random breath testing in NSW and its implications for drug driving legislation. Australian Drug and Alcohol Review 7, 243-250.
768. Prescott, J. (1988). Research issues and priorities in methadone maintenance. Australian Drug and Alcohol Review 7, 375-381.
769. Prescott, J. (1990). Kava use in Australia. Drug and Alcohol Review 9, 325-331.
770. Prescott, J., Jamieson, D., Edmur, N., & Duffield, P. (1993). Acute effects of kava on measures of cognitive performance, physiological function and mood. Drug & Alcohol Review 12, 49-58.
771. Prescott, J. & Saunders, J. (eds) (1987). Proceedings of the Conference on Early Detection and Intervention for Persons with Harmful Alcohol and Drug Use, University of Sydney, December, 1985. Australian Drug and Alcohol Review 6, 283-358.
772. Prestage, G., Degenhardt, L. Jin, F., Grulich, A., Imrie, J., Kaldor, J., & Kippax, S. (2007). Predictors of frequent use of amphetamine type stimulants among HIV-negative gay men in Sydney, Australia. Drug and Alcohol Dependence 91, 260-268.
773. Proudfoot, H., Baillie, A. & Teesson, M. (2005). The structure of alcohol dependence in the community. Drug and Alcohol Dependence 81, 21-26. (abstract available)
774. Proudfoot, H. & Teesson, M. (2001). Women and schizophrenia (Book review). Australian and New Zealand Journal of Psychiatry 35, 698.
775. Proudfoot, H. & Teesson, M. (2002). Who seeks treatment for alcohol dependence? Findings from the Australian National Survey of Mental Health and Wellbeing. Social Psychiatry and Psychiatric Epidemiology 37, 451-456. (abstract available)
776. Proudfoot, H., & Teesson, M. (2009). The association of alcohol dependence with general practice attendance. Drug and Alcohol Review 28(2), 154-159.
777. Quinn, D., Wodak, A., & Day, R. (1997). Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clinical Pharmacokinetics 33, 344-400.
778. Rasmussen, N. (2008). America's first amphetamine epidemic 1929-1971 - A quantitative and qualitative retrospective with implications for the present. American Journal of Public Health, 98(6), 974-985.
779. Razali, K., Thein, H.H., Bell, J., Cooper-Stanbury, M, Dolan, K., Dore, G., George, J., Kaldor, J., Karvelas, M., Li, J., Maher, L., McGregor, S., Hellard, M., Poeder, F., Quaine, J., Stewart, K., Tyrrell, H., Weltman, M., Westcott, O., Wodak, A., & Law, M. (2007). Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence 91, 228-235.
780. Rea, F., Bell, J.R., Young, M.R., & Mattick R.P. (2004). A randomized controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug and Alcohol Dependence 75, 79-88.
781. Reid, A., Lynskey, M., & Copeland, J. (2000). Cannabis use among Australian adolescents: Findings of the 1998 National drug Strategy Household Survey. Australian and New Zealand Journal of Public Health 24, 596- 602.
782. Reid, S. C., Ukoumunne, O. C., Coffey, C., Teesson, M., Carlin, J. B., & Patton, G. C. (2007). Problem alcohol use in young Australian adults. Australian and New Zealand Journal of Psychiatry, 41, 436-441.
783. Reilly, D., Didcott, P., Swift, W., & Hall, W. R. (1998). Long-term cannabis use: Characteristics of users in an Australian rural area. Addiction 93, 837-846.
784. Rey, J., Sawyer, M.G., Raphael, B., Patton, G.C., & Lynskey, M. (2002). The mental health of teenagers who use marijuana: Results of an Australian survey. British Journal of Psychiatry 180, 216-221.
785. Richardson, K., Baillie, A., Reid, S., Morley, K., Teesson, M., Sannibale, C., et al. (2008). Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction, 103(6), 953-959.
786. Richardson, K., Reid, S. C., Morley, K. C., Teesson, M., Sannibale, C., Weltman, M., et al. (2006). The effects of alcohol and naltrexone on craving and alcohol consumption. Alcoholism-Clinical and Experimental Research, 30(9), 169A-169A.
787. Richmond, R. (1993). Physicians can help patients to stop smoking. Fellowship Affairs, newsletter of the Royal College of Physicians.
788. Richmond, R. (1993). Increasing resource allocation into tobacco control activities: A comprehensive approach including primary prevention and treatment including brief intervention. Drug and Alcohol Review 12, 205-215.
789. Richmond, R.L., Gnovak, K., Kehoe, L., Calfas, G., Mendelsohn, C.P., & Wodak, A. (1998). Effect of training on general practitioners' use of a brief intervention for excessive drinkers. Australian and New Zealand Journal of Public Health 22, 206-209.
790. Richmond, R.L. & Heather, N. (1990). General practitioner interventions for smoking cessation: Past results and future prospects. Behaviour Change 7, 110-119.
791. Richmond, R., Heather, N., & Holt, P. (1996). Restrictions on tobacco and alcohol use in Australian work-places. Drug and Alcohol Review 15, 377-383.
792. Richmond, R., Heather, N., & Holt, P. (1996). Programmes for tobacco and alcohol users in Australian work-places. Drug and Alcohol Review 15, 385 -392.
793. Richmond, R. & Kehoe, L. (1997). Smoking behaviour and attitudes among Australian medical students. Medical Education 31, 169-176.
794. Richmond, R., Kehoe, L., & de Almedia Neto, A. C. (1997). Effectiveness of a 24-hour transdermal nicotine patch in conjunction with a cognitive behavioural programme: one year outcome. Addiction 92, 27-31.
795. Richmond, R.L., Kehoe, L., Hailstone, S., Wodak, A. & Uebel-Yan, M. (1999). Quantitative and qualitative evaluations of brief interventions to change excessive drinking, smoking and stress in the police force. Addiction 94, 1509-1521.
796. Richmond, R.L., Kehoe, L., & Webster, I.W. (1993). Weight change after smoking cessation in general practice. Medical Journal of Australia 158, 821-822.
797. Richmond, R., Makinson, R., Kehoe, L., Giugni, A., & Webster, I. (1993). A one year evaluation of three smoking cessation programmes administered by general practitioners. Addictive Behaviours 18, 187-199.
798. Richmond, R.L. & Webster, I.W. (1990). Which anti-smoking programme? (letter to the editor). Medical Journal of Australia 154, 367.
799. Richmond, R.L. & Wodak, A. (1998). Where should alcohol and tobacco interventions be provided? Australian and New Zealand Journal of Public Health 22, 745-746.
800. Richmond, R.L., Wodak, A., Bourne, S., & Heather, N. (1998). Screening for unhealthy lifestyle factors in the workplace. Australian and New Zealand Journal of Public Health 22, 324-331.
801. Richmond, R.L., Wodak, A., Kehoe, L., & Heather, N. (1998). How healthy are the police? A survey of lifestyle factors. Addiction 93, 1729-1737.
802. Riddell, S., Shanahan, M., Degenhardt, L., & Roxburgh, A. (2008). Estimating the costs of drug-related hospital separations in Australia. Australian and New Zealand Journal of Public Health, 32(2), 156-161.
803. Riddell, S., Shanahan, M., Degenhardt, L., & Roxburgh, A. (2008). A review of the use of US-derived aetiological fractions in an Australian setting for antenatal problems related to cocaine use. Australian and New Zealand Journal of Public Health, 32(4), 393-394.
804. Ritter, A. (2006). Drug and Alcohol Review: Editorial. Drug and Alcohol Review, 25(5), 391-392.
805. Ritter, A. (2006). Studying illicit drug markets: Disciplinary contributions. International Journal of Drug Policy, 17(6), 453-463.
806. Ritter, A. (2007). Comparing alcohol policies between countries: Science or silliness? Plos Medicine, 4(4), 616-618.
807. Ritter, A. (2007). Methamphetamine alarm: Are we forgetting what we know? Drug and Alcohol Review, 26(3), 227-230.
808. Ritter, A. (2008). Speaking truth to power. Drug and Alcohol Review, 27(2), 113-114.
809. Ritter, A. (2009). How do drug policy makers access research evidence? International Journal of Drug Policy 20(1), 70-75.
810. Ritter, A., Bammer, G., Hamilton, M., & Mazerolle, L. (2007). Effective drug policy: A new approach demonstrated in the Drug Policy Modelling Program. Drug and Alcohol Review, 26(3), 265-271.
811. Ritter, A., & Cameron, J. (2006). A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. Drug and Alcohol Review, 25(6), 611-624.
812. Ritter, A., & Cameron, J. (2007). Australian clinician attitudes towards contingency management: Comparing down under with America. Drug and Alcohol Dependence, 87(2-3), 312-315.
813. Ritter, A., & McDonald, D. (2008). Illicit drug policy: Scoping the interventions and taxonomies. Drugs: Education Prevention and Policy, 15(1), 15-35.
814. Roche, A., Saunders, J. Parle, M., Hall, W., & Stubbs, J. (1995). Management and treatment efficacy of drug and alcohol problems: What do doctors believe? Addiction 90, 1357-1366.
815. Rodgers, B., Parslow, R. & Degenhardt, L. (2007). Affective disorders, anxiety disorders and psychological distress in non-drinkers. Journal of Affective Disorders 99, 165-172.
816. Rollnick, S., Heather, N., & Bell, A. (1992). Negotiating behaviour change in medical settings: The development of brief motivational interviewing. Journal of Mental Health 1, 25-37.
817. Rollnick, S., Heather, N., Gold, R., & Hall, W. (1992). Development of a short ‘readiness to change’ questionnaire for use in brief, opportunistic interventions among excessive drinkers. British Journal of Addiction 87, 743-754.
818. Rosen, A., Mueser, K., & Teesson, M. (2007). Assertive community treatment: Issues from scientific and clinical literature with implications for practice. Journal of Rehabilitation Research and Development 44, 813-826.
819. Rosen, A. & Teesson, M. (2001). Does case management work? The evidence and the abuse of evidence-based medicine. Australian and New Zealand Journal of Psychiatry 35, 731-746. (A Corrigendum to this article has been published in the Australian and New Zealand Journal of Psychiatry 36, 288.)
820. Ross, M.W. & Darke, S. (1992). Mad, bad and dangerous to know: Dimensions and measurement of attitudes toward injecting drug users. Drug and Alcohol Dependence 30, 71-74.
821. Ross, J. & Darke, S. (2000). The nature of benzodiazepine dependence among heroin users in Sydney, Australia. Addiction 95, 1785-1793. (abstract available)
822. Ross, J., Darke, S., & Hall, W. (1996). Benzodiazepine use among heroin users in Sydney: patterns of use, availability and procurement. Drug and Alcohol Review 15, 237-243.
823. Ross, J., Darke, S. & Hall, W. (1997). Transitions between routes of benzodiazepine administration among heroin users in Sydney. Addiction 92, 697-705.
824. Ross, M.W., Gold, J., Wodak, A.D., & Miller, M.E. (1991). Sexually transmissible diseases in injecting drug users. Genitourinary Medicine 67, 32-36.
825. Ross, M.W., Stowe, A., Wodak, A., Miller, M.E., & Gold, J. (1993). A comparison of drug use and HIV infection risk behaviour between injecting drug users in treatment, previously-in-treatment and never in treatment. Journal of Acquired Immunodeficiency Syndromes 6, 518-528.
826. Ross, J., Teesson, M., Darke, S., Lynskey, M., Ali, R., Ritter, A., & Cooke, R. (2005). The characteristics of heroin users entering treatment: Findings from the Australian treatment outcome study (ATOS). Drug and Alcohol Review 24, 411-418. (abstract available)
827. Ross, J., Teesson, M., Darke, S., Lynskey, M., Ali, R., Ritter, A., & Cooke R. (2006). Short-term outcomes for the treatment of heroin dependence: Findings from Australian Treatment Outcome Study (ATOS). Addictive Disorders and Their Treatment 5, 133-144.
828. Ross, M.W., Wodak, A., & Gold, J. (1993). Accuracy of self-reporting of sexually transmissible disease in injecting drug users (Letter). Journal of the European Academy of Dermatology and Venereology 2, 147-148.
829. Ross, M.W., Wodak, A.D., Gold, J., & Miller, M.E. (1992). Differences across sexual orientation on HIV risk behaviours in injecting drug users. AIDS Care 156, 139-148.
830. Ross, M.W., Wodak, A., Miller, M.E., & Gold, J. (1993). Sexual partner choice in injecting drug users from a “critical incident” measure: Its implications for assessing risk of HIV Spread. Sexological Review 1, 77-92.
831. Rouen, D. & Dolan, K. (2001). Supporting needle and syringe programs in Australia (Letter). Australian and New Zealand Journal of Public Health 25, 187.
832. Roxburgh, A. & Degenhardt, L. (2008). Characteristics of drug-related hospital separations in Australia. Drug and Alcohol Dependence 92, 149–155.
833. Roxburgh, A., Degenhardt, L. & Breen, C. (2004). Changes in patterns of drug use among injecting drug users following changes in the availability of heroin in New South Wales, Australia. Drug and Alcohol Review 23, 287-294.
834. Roxburgh, A., Degenhardt, L. & Breen, C. (2005). Drug use and risk behaviours among injecting drug users: A comparison between sex workers and non-sex workers in Sydney, Australia. Harm Reduction Journal 2:7.
835. Roxburgh, A., Degenhardt, L. & Copeland, J. (2006). Post-traumatic stress disorder among female street-based sex workers in the greater Sydney, area, Australia. BMC Psychiatry 6: 24.
836. Roxburgh, A., Degenhardt, L., Copeland, J., & Larance, B. (2008). Drug dependence and associated risks among female street-based sex workers in the greater Sydney area, Australia. Substance Use & Misuse, 43(8-9), 1202-1217.
837. Rubin, G.L., Schofield, W.N., Dean, M.G., & Shakeshaft, A.P. (2001). Appropriateness of red blood cell transfusions in major urban hospitals and effectiveness of an intervention. Medical Journal of Australia 175, 354-358.
838. Rutter, S., Dolan, K., & Wodak, A. (1997). Rooms for rent: injecting and harm reduction in Sydney (Letter to the Editor). Australian and New Zealand Journal of Public Health 21,105.
839. Saltman, D.C. & Mant, A. (1992). General practitioner data bases in Australia. Medical Journal of Australia 156, 16-20.
840. Sannibale, C. & Hall, W. (1998). An evaluation of Cloninger’s typology of alcohol abuse. Addiction 93, 1242-1250.
841. Sannibale, C. & Hall, W. (2001). Gender related symptoms and correlates of alcohol dependence among men and women with a lifetime diagnosis of alcohol use disorders. Drug and Alcohol Review 20, 369-383.
842. Scheier, L. A., Ben Abdallah, A., Inciardi, J. A., Copeland, J., & Cottler, L. B. (2008). Tri-city study of Ecstasy use problems: A latent class analysis. Drug and Alcohol Dependence, 98(3), 249-263.
843. Schofield, D., Tennant, C., Nash, L., Degenhardt, L., Cornish, A., Hobbs, C., & Brennan, G. (2006). Reasons for cannabis use in psychosis. Australian and New Zealand Journal of Psychiatry 40, 570-574.
844. Shakeshaft, A.P., Bowman, J.A., Burrows, S., Doran, C. & Sanson-Fisher, R.W. (2002). Community-based alcohol counselling: A randomized clinical trial. Addiction 97, 1449-1463.
845. Shakeshaft, A.P., Bowman, J.A. & Sanson-Fisher, R.W. (2002). Community-based drug and alcohol counselling: Who attends and why? Drug and Alcohol Review 21,153-162. (abstract available)
846. Shakeshaft, A., Fawcett, J., Mattick, R.P., Richmond, R., Wodak, A., Harris, M.F., & Doran, C. (2006). Patient-driven computers in primary care: Their use and feasibility.Health Education 106, 400-411.
847. Shakeshaft, A., Nassirimanesh, B., Day, C., & Dolan, K. (2005). Perceptions of substance use, treatment options and training needs among Iranian primary care physicians. International Journal for Equity in Health 4: 7.
848. Shanahan, M., Doran, C., Digiusto, E., Bell, J., Lintzeris, N., White, J., Ali, R., Saunders, J., Mattick, R., & Gilmour, S. (2006). A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addictive Behaviours 31, 371-387.
849. Shanahan, M., Doran, C., Gates, J., Shakeshaft, A., & Mattick, R.P. (2003). The cost effectiveness of pharmacotherapies for smoking cessation: Necessary but not sufficient? Applied Health Economics and Health Policy 2, 76-78.
850. Shanahan, M., Havard, A., Teesson, M., Mills, K., Williamson, A., & Ross, J. (2006). Patterns and costs of treatment for heroin dependence over 12 months: Findings from the Australian Treatment Outcome Study. Australian and New Zealand Journal of Public Health 30, 305-311.
851. Shanahan, M. Shakeshaft, A. & Mattick, R.P. (2006). Modelling the costs and outcomes of changing rates of screening for alcohol misuse by GPs in the Australian context. Applied Health Economics Health Policy 5, 155-166.
852. Shand, F. & Mattick, R.P. (2002). Results from the 4th National Clients of Treatment Service Agencies census: Changes in clients’ substance use and other characteristics. Australian and New Zealand Journal of Public Health 26, 352-357. (abstract available)
853. Shand, F., Topp, L., Darke, S., Makkai, T., & Griffiths, P. (2003). The monitoring of drug trends in Australia. Drug and Alcohol Review 22, 61-72. (abstract available)
854. Shanley, C., Lodge, M., & Mattick, R.P. (1996). The dissemination of research findings to alcohol and other drug practitioners. Drug and Alcohol Review 15, 89-94.
855. Shearer, J. (2002). Cocaine Addiction Theory, Research and Treatment (book review). Drug and Alcohol Review 21, 188-189.
856. Shearer, J. (2007). Psychosocial approaches to psychostimulant dependence: A systematic review. Journal of Substance Abuse Treatment 32, 41-52.
857. Shearer, J. (2008). The principles of agonist pharmacotherapy for psychostimulant dependence. Drug and Alcohol Review, 27(3), 301-308.
858. Shearer, J., Darke, S., Rodger, C., Slade, T., van Beek, I., Lewis, J., et al. (2009). A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 104(2), 224-233.
859. Shearer, J. & Gowing, L. (2004). Pharmacotherapies for problematic psychostimulant use: A review of current research. Drug and Alcohol Review 23, 203-211.
860. Shearer, J., Johnston, J., Fry, C.L., Kaye, S., Dillon, P., Dietze, P., & Collins, L. (2007). Contemporary cocaine use patterns and associated harms in Melbourne and Sydney, Australia. Drug and Alcohol Review 26, 537-543.
861. Shearer, J., Johnston, J., Fry, C.L., Kaye, S., Dillon, P., Dietze, P., & Collins, L.(2008). An Australian Profile on Cocaine Supply. The Howard Journal, 47(1), 67-88.
862. Shearer, J. & Shanahan, M. (2006). Cost effectiveness analysis of smoking cessation interventions. Australian and New Zealand Journal of Public Health 30, 428-434.
863. Shearer, J., Sherman, J., Wodak, A., & Van Beek, I. (2002). Substitution therapy for amphetamine users. Drug and Alcohol Review 21, 179-185. (abstract available)
864. Shearer, J., White, B., Gilmour, S., Wodak, A., & Dolan, K. (2006). Hair analysis underestimates heroin use in prisoners. Drug and Alcohol Review 25, 425-431.
865. Shearer, J., Wodak, A. & Dolan, K. (2007). Evaluation of a prison-based naltrexone program. International Journal of Prisoner Health 3, 214-224.
866. Shearer, J., Wodak, A., Mattick, R.P., van Beek, I., Lewis, J., Hall, W., & Dolan, K. (2001). Pilot randomised controlled study of dexamphetamine for amphetamine dependence. Addiction 96, 1289-1296.
867. Shearer, J., Wodak, A., van Beek, I., Mattick, R.P., & Lewis, J. (2003). Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 98, 1137-1141. (abstract available)
868. Shortt, A., Hutchinson, D., Chapman, R., & Toumbourou, J. (2007). Family, school, peer and individual influences on early adolescent alcohol use: First-year impact of the Resilient Families programme. Drug and Alcohol Review 26, 625 – 634.
869. Sibthorpe, B., Bailie, R., Brady, M., Ball, S., Sumnerdodd, P., & Hall, W. (2002) The demise of a planned randomised controlled trial in an urban Aboriginal Medical Service. Medical Journal of Australia, 176, 273-276.
870. Silins, E., Conigrave, K. M., Rakvin, C., Dobbins, T., & Curry, K. (2007). The influence of structured education and clinical experience on the attitudes of medical students towards substance misusers. Drug and Alcohol Review 26, 191-200.
871. Silins, E., Copeland, J. & Dillon, P. (2007.) Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: Hierarchy of risk. Australian and New Zealand Journal of Psychiatry 41, 649-655.
872. Silins, E., Sannibale, C., Larney, S., Wodak, A., & Mattick, R. (2008). Residential detoxification: Essential for marginalised, severely alcohol- and drug-dependent individuals. Drug and Alcohol Review 27(4), 414-419.
873. Simon, N.G. & Mattick, R.P. (2002). The impact of regular ecstasy use on memory function. Addiction 97, 1523-1530.
874. Simon, N. & Mattick, R.P. (2003). Psychostimulant use, polydrug use and memory functioning: A reply to Parrott et al. Letter to the Editor. Addiction 98, 1003-1005.
875. Simpson, M., Lawrinson, P., Copeland, J., & Gates, P. (2009). The Alcohol Treatment Outcome Measure (ATOM): A new clinical tool for standardising outcome measurement for alcohol treatment. Addictive Behaviours 34(1), 121-124.
876. Singleton, J., Degenhardt, L., Hall, W. & Zabransky, T. (2009). Mortality among amphetamine users: A systematic review of cohort studies. Drug and Alcohol Dependence 105, 1-8.
877. Slade, T., Grove, R., & Teesson, M. (2009). A taxometric study of alcohol abuse and dependence in a general population sample: evidence of dimensional latent structure and implications
for DSM-V. Addiction 104(5), 742-751.
1. Solowij, N. (1993). Ecstasy (3, 4 methylene-dioxymethamphetamine). Current Opinion in Psychiatry 6, 411-415. (abstract available)
2. Solowij, N. (1995). Do cognitive impairments recover following cessation of cannabis use? Life Sciences 56, 2119-2126. (abstract available)
3. Solowij, N. & Grenyer, B. (2002). Are the adverse consequences of cannabis use age-dependent? (Editorial). Addiction 97, 1083-1086.
4. Solowij, N., Grenyer, B.F.S., Chesher, G., & Lewis, J. (1995). Biopsychosocial changes associated with cessation of cannabis use: A single case study of acute and chronic cognitive effects, withdrawal and treatment. Life Sciences 56, 2127-2134. (abstract available)
5. Solowij, N., Hall, W., & Lee, N. (1992). Recreational MDMA use in Sydney: A profile of ‘Ecstasy’ users and their experiences with the drug. British Journal of Addiction 87, 1161-1172.
6. Solowij, N., Michie, P.T., & Fox, A.M. (1991). Effects of long term cannbis use on selective attention: An event-related potential study. Pharmacology, Biochemistry and Behaviour 40, 683-688.
7. Solowij, N., Michie, P.T., & Fox, A.M. (1993). Frequency and duration of cannabis use differentially affect brain function in a selective attention task. International Journal of Neuroscience 71, 107-133.
8. Solowij, N., Michie, P.T., & Fox, A.M. (1995). Differential impairments of selective attention due to frequency and duration of cannabis use. Biological Psychiatry 37, 731-739. (abstract available)
9. Solowij, N., Stephens, R.S., Roffman, R.A., Babor, T., Kadden, R., Miller, M., Christiansen, K., McRee, B., & Vendetti, J. (2002). Cognitive functioning of long-term heavy cannabis users seeking treatment. Journal of the American Medical Association 287, 1123-1131.
10. Southgate, E., Weatherall, A.M., Day, C., & Dolan, K. (2005). What’s in a virus? Folk understandings of hepatitis C infection and infectiousness among injecting drug users in Kings Cross, Sydney. International Journal for Equity in Health 4:5.
11. Spooner, C. (1995). Adolescent Substance Abuse. A Comprehensive Guide to Theory and Practice (book review). Drug and Alcohol Review 14, 137-138.
12. Spooner, C. (1995). Preschoolers and Substance Abuse: Strategies for prevention and intervention. Drug and Alcohol Review 14, 417-418.
13. Spooner, C. (1998). The etiology and prevention of drug abuse among minority youth. Drug and Alcohol Review 17, 333-334.
14. Spooner, C. (1999). Causes and correlates of adolescent drug abuse and implications for treatment. Drug and Alcohol Review 18, 453-475. (abstract available)
15. Spooner, C. (2005). Structural determinants of drug use – a plea for broadening our thinking (Editorial). Drug and Alcohol Review 24, 89-92.
16. Spooner, C., Bishop, J., & Parr, J. (1996). Research methods for studying injecting drug users in a non-metropolitan setting. Drug and Alcohol Review 16, 349-355.
17. Spooner, C., Bishop, J., & Parr, J. (1996). Unsafe injecting practices and risk reduction in a non-metropolitan setting. Health Promotion Journal of Australia 6, 54-56.
18. Spooner, C. & Hall, W. (2002). Preventing drug misuse by young people: We need to do more than ‘just say no’ (Editorial). Addiction 97, 478-481.
19. Spooner, C. & Hall, W. (2002). Public policy and the prevention of substance-use disorders. Current Opinion in Psychiatry 15, 235-9. (abstract available)
20. Spooner, C., Hall, W., & Mattick, R. (2001). An overview of diversion strategies for drug-related offenders. Drug and Alcohol Review 20, 281-94.
21. Spooner, C., Mattick, R., & Noffs, W. (2001). A study of the patterns and correlates of substance use among adolescents applying for treatment. Australia & New Zealand Journal of Public Health 24, 492-502.
22. Spooner, C., Mattick, R.P., & Noffs, W. (2001). Outcomes of a comprehensive treatment program for adolescents with a substance-use disorder. Journal of Substance Use Treatment 20, 205-213. (abstract available)
23. Stevenson, R., Copeland, J. & Gates, P. (2007) The role of experience in liking “Ready-to-drinks”. Psychology of Addictive Behaviours 21, 564-569.
24. Stimson, G., Alldritt, L., Dolan K, & Donoghoe, M. (1988). Syringe Exchange Schemes for drug users in England and Scotland. British Medical Journal 296, 1717-1719.
25. Stimson, G., Alldritt, L., Dolan, K., & Donoghoe, M. (1988). HIV transmission risk behaviour of clients attending syringe exchange schemes in England and Scotland. British Journal of Addiction 83, 1449.
26. Stimson, G., Dolan, K., Donoghoe, M., & Alldritt L. (1988). Syringe Exchange 1. Drug Link 3, 10-11.
27. Stimson, G., Dolan, K., Donoghoe, M., Alldritt, L., & Lart, R. (1988). Syringe Exchange 3. Can injectors change ? Drug Link 4, 10-11.
28. Stimson, G.V,, Dolan, K., Donoghoe, M., & Lart, R. (1989). The pilot syringe exchange project in England and Scotland: A summary of the evaluation. British Journal of Addiction 84, 1283- 1284.
29. Stimson, G.V,, Dolan, K., Donoghoe, M., & Lart, R. (1990). The future of UK syringe exchange in the public health prevention of HIV infection. International Journal of Drug Policy 2, 14-17.
30. Stimson, G, Donoghoe, M,, Alldritt, L,, & Dolan, K. (1988). Syringe Exchange 2. The Clients. Drug Link 3, 8-9.
31. Stimson G, Donoghoe M, Dolan K and Alldritt L. (1988). A volatile time for British Drug Policies: A commentary on drug misuse and AIDS prevention. Policy on the right track ? British Journal of Addiction 83, 1241-1242.
32. Stowe, A., Wodak, A., & Ross, M.W. (1992). Contact between injecting drug users and general practitioners and its implications for health education. Journal of the Royal Society on Health 112, 125-126.
33. Strang, J., Darke, S., Hall, W., Farrell, M., & Ali, R. (1996). Heroin overdose: Is there a case for take-home naloxone? (Editorial). British Medical Journal 312, 1435.
34. Strang, J., Witton, J., & Hall, W. (2000). Improving the quality of the cannabis policy debate: Defining the different domains. British Medical Journal 320 , 108-110.
35. Swift, W. (1991). Helping to prevent relapse: The role of ‘cue exposure’. Drugwise, February.
36. Swift, W., Coffey, C., Carlin, J. B., Degenhardt, L., Calabria, B., & Patton, G., C. (2009). Are adolescents who moderate their cannabis use at lower risk of later regular and dependent cannabis use? Addiction 104(5), 806-814.
37. Swift, W., Coffey, C., Carlin, J. B., Degenhardt, L., & Patton, G. C. (2008). Adolescent cannabis users at 24 years: Trajectories to regular weekly use and dependence in young adulthood. Addiction, 103(8), 1361-1370.
38. Swift, W. & Copeland, J. (1996). Treatment needs and experiences of Australian women with alcohol and other drug related problems. Drug and Alcohol Dependence 40, 211-219.
39. Swift, W. & Copeland, J. (1998). Treatment needs of women with alcohol and other drug problems: Experiences and views of Australian treatment personnel. Drug and Alcohol Review 17, 59-67.
40. Swift, W., Copeland, J., & Hall, W. (1996). Characteristics of women with alcohol and other drug problems: findings of an Australian national survey. Addiction 91, 1141-1150.
41. Swift, W., Copeland, J., & Hall, W. (1998). Choosing a diagnostic cut-off for cannabis dependence. Addiction 93, 1681-1692.
42. Swift, W., Copeland, J., Howard, J., Roffman, R.A., Stephens, R.S. & Berghuis, J. (2001). Adolescent cannabis check-up and intervention trial. Drug and Alcohol Dependence 63(s1), s156.
43. Swift, W., Copeland, J., & Lenton, S. (2000). Cannabis and harm reduction. Drug and Alcohol Review 19, 101-112.
44. Swift, W., Gates, P. & Dillon, P. (2005). Survey of Australians using cannabis for medical purposes. Harm Reduction Journal 2:18. (abstract available)
45. Swift, W., Hall, W. & Copeland, J. (1998). Characteristics of long-term cannabis users in Sydney, Australia. European Addiction Research 4, 190-197.
46. Swift, W., Hall, W., & Copeland, J. (2000). One year follow-up of cannabis dependence among long-term users in Sydney, Australia. Drug and Alcohol Dependence 59, 309-318.
47. Swift, W., Hall, W., & Didcott, P. (1998). Patterns and correlates of cannabis dependence among long-term users in an Australian rural area. Addiction 93, 1149-1160.
48. Swift, W., Hall, W., Didcott, P. & Reilly, D. (1998). Patterns and correlates of cannabis dependence among long-term users in an Australian rural area. Addiction 93, 1149-1160.
49. Swift, W., Hall, W., & Teesson, M. (2001). Cannabis use and dependence among Australian adults: Results from the National Survey of Mental Health and Wellbeing. Addiction 96, 737-748. (abstract available)
50. Swift, W., Hall, W., & Teesson, M. (2001) Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: Results from the National Survey of Mental Health and Wellbeing. Drug and Alcohol Dependence 63, 147-153.
51. Swift, W., Maher, L. & Sunjic, S. (1998) Transitions between routes of heroin administration: A study of Caucasian and Indochinese heroin users in south-western Sydney, Australia. Addiction 94, 71-82.
52. Swift, W., Stollznow, N. & Pirotta, M. (2007). The use of alcohol and medicines among Australian adults. Australian and New Zealand Journal of Public Health 31, 529-532.
53. Swift, W., Williams, G., Neill, O., & Grenyer, B. (1990). Prevalence of minor psychopathology in opioid users seeking treatment. British Journal of Addiction 85, 629-634.
54. Tabakoff, B., Helander, A., Conigrave, K.M., Martinez, L., Hoffman, P.L., Whitfield, J., Degenhardt, L., Saunders, J., Baron, A., Glanz, J., & Members of the WHO/ISBRA Study Group (2001). WHO/ISBRA Study on State and Trait Markers in Alcoholism. Alcoholism: Clinical and Experimental Research 25, 99S-103S.
55. Taylor, S., Choucair, A., Shaw, J., & Copeland, J. (2000). Assessment of need for information on illicit drugs in the Arabic, Chinese and Vietnamese languages. Australian Family Physician 29, 725-726.
56. Teesson, M. (1999). Drug education: Early education vital. Directions in Education 8, 2-3.
57. Teesson, M. (2000). Management of Drug Users in the Community: A practical handbook. (book review) Addiction 94, 1751.
58. Teesson, M. (2001). Practical measures in psychiatry (book review). Medical Journal of Australia 175, 417.
59. Teesson, M. (2008). Recognition and prevention of major mental and substance use disorders. Addiction, 103(5), 857-858.
60. Teesson, M., Baillie, A., Lynskey, M., Manor, B., & Degenhardt, L. (2006). Substance use, dependence and treatment seeking in the United States and Australia: A cross-national comparison. Drug and Alcohol Dependence 81, 149-155.
61. Teesson, M., Dietrich, U., Degenhardt, L., Lynskey, M., & Beard, J. (2002). Substance use disorders in an Australian community survey. Drug and Alcohol Review 21, 275-280. (abstract available)
62. Teesson, M. & Gallagher, J. (1998). Evaluation of a treatment programme for serious mental illness and substance use in an inner city area. Journal of Mental Health 8, 19-28.
63. Teesson, M., Hall, W., Lynskey, M., & Degenhardt, L. (2000). Alcohol and drug-use disorders in Australia: Implications of the National Survey of Mental Health and Wellbeing. Australian and New Zealand Journal of Psychiatry 34, 206-213. (abstract available)
64. Teesson, M., Havard, A., Fairbairn, S., Ross, J., Lynskey, M., & Darke, S. (2005). Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): Prevalence, correlates and treatment seeking. Drug and Alcohol Dependence 78, 309-315.
65. Teesson, M., Havard, A., Ross, J., & Darke, S. (2006). Outcomes after detoxification for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Review 25, 241-247.
66. Teesson, M., Hodder, T., & Buhrich, N. (2000). Substance use disorders among homeless people in inner Sydney. Social Psychiatry and Psychiatric Epidemiology 35, 451-456.
67. Teesson, M., Hodder, T. & Buhrich, N. (2003). Alcohol and other drug use disorders among homeless people in Australia. Substance Use and Misuse 38, 465-476.
68. Teesson, M., Lynskey, M., Manor, B., & Baillie, A. (2002). The structure of cannabis dependence in the community. Drug and Alcohol Dependence 68, 255-262.
69. Teesson, M., Mills, K., Ross, J., Darke, S., Williamson, A. & Havard, A. (2007). The impact of treatment on 3 years’ outcome for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Addiction 103, 80-88.
70. Teesson, M., Ross, J., Darke, S., Lynskey, M., Ali, R., Cooke, R., & Ritter, A. (2006). One year outcomes for heroin dependence: Findings from the Australian Treatment Outcome Sudy (ATOS). Drug and Alcohol Dependence 83, 174-180.
71. Teesson, M., Slade, T., & Mills, K. (2009). Comorbidity in Australia: findings of the 2007 National Survey of Mental Health and Wellbeing. Australian and New Zealand Journal of Psychiatry 43(7), 606-614.
72. Thein, H., Kimber, J., Maher, L., MacDonald, M., & Kaldor, J. (2005). Public opinion towards supervised injecting centres and the Sydney Medically Supervised Injecting Centre. International Journal of Drug Policy 16, 275-280.
73. Thomson, C. L., Morley, K. C., Teesson, M., Sannibale, C., & Haber, P. S. (2008). Issues with recruitment to randomised controlled trials in the drug and alcohol field: A literature review and Australian case study. Drug and Alcohol Review, 27, 115-122.
74. Topp, L., Barker, B. & Degenhardt, L. (2004). The external validity of results derived from ecstasy users recruited using purposive sampling strategies. Drug and Alcohol Dependence 73, 33-40. (abstract available)
75. Topp, L., Breen, C., Kaye, S. & Darke, S. (2004) Adapting the illicit drug reporting system (IDRS) to examine the feasibility of monitoring trends in the markets for 'party drugs'. Drug and Alcohol Dependence 73, 189-197. (abstract available)
76. Topp, L. & Darke, S. (1997). The applicability of the dependence syndrome to amphetamine. Drug and Alcohol Dependence 48, 113-118.
77. Topp, L., Day, C. & Degenhardt, L. (2003). Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug and Alcohol Dependence 70, 275-286. (abstract available)
78. Topp, L., Degenhardt, L., Day, C., & Collins, L. (2003). Contemplating drug monitoring systems in the light of Australia’s ‘heroin shortage’ (Editorial). Drug and Alcohol Review 22, 3-6.
79. Topp, L., Degenhardt, L., Kaye, S., & Darke, S. (2003). The emergence of potent forms of methamphetamine in Sydney, Australia: A case study of the IDRS as a strategic early warning system. Drug and Alcohol Review 21, 341-348.
80. Topp, L., Hando, J. & Dillon, P. (1999). Sexual behaviour of ecstasy users in Sydney, Australia. Culture Health and Sexuality 1, 147-160. (abstract available)
81. Topp, L., Hando, J., Dillon, P., Roche, A. & Solowij, N. (2000) Ecstasy use in Australia: Patterns of use and associated harm. Drug and Alcohol Dependence 55, 105-115. (abstract available)
82. Topp, L., Lovibond, P.F., & Mattick, R.P. (1998) Cue reactivity in dependent amphetamine users: Can monistic conditioning theories improve our understanding of reactivity? Drug and Alcohol Review 17, 277-288.
83. Topp, L., & Mattick, R.P. (1997). Validation of the amphetamine dependence syndrome and the SamDQ. Addiction 92, 151-162.
84. Topp, L. & Mattick, R.P. (1997). Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction 92, 839-845.
85. Topp, L. & McKetin, R. (2003). Supporting evidence-based policy-making: A case study of the Illicit Drug Reporting System in Australia. In Bulletin On Narcotics Volume LV, Nos 1 and 2, 2003. The practice of drug abuse epidemiology. Vienna: United Nations Office on Drugs and Crime. (abstract available)
86. Turnbull, P.J., Dolan, K.A., & Stimson, G.V. (1993). HIV testing and the care and treatment of HIV positive people in English prisons. AIDS Care 5, 199-206.
87. Turnbull, P., Stimson, G.V. & Dolan, K. (1992). Prevalence of HIV infection among exprisoners in England. Brit ish Medical Journal 304, 90-91.
88. Velicer, W., Redding, C.A., Richmond, R., Greeley, J., & Swift, W. (1992). A time series investigation of alternative measures of smoking habit strength. Addictive Behaviours 17, 325-345.
89. Vimpani, G. & Spooner, C. (2003). Minimizing substance misuse by strategies to strengthen families. Drug and Alcohol Review 22, 251-254.
90. Vogl, L., Teesson, M., Andrews, G., Bird, K., Steadman, B., & Dillon, P. (2009). A computerized harm minimization prevention program for alcohol misuse and related harms: randomized controlled trial. Addiction 104(4), 564-575.
91. Wallace, C., Burns, L., Gilmour, S., & Hutchinson, D. (2007). Substance use, psychological distress and violence among pregnant and breastfeeding Australian women. Australian and New Zealand Journal of Public Health 31, 51-56.
92. Ward, J., Bell, J., Mattick, R.P., & Hall, W. (1996). Methadone maintenance therapy for opioid dependence: A guide to appropriate use. CNS Drugs 6, 440-449.
93. Ward, J., Bell, J., Mattick, R.P., & Hall, W. (1996). Methadone maintenance therapy: A guide to appropriate use. New Ethicals: New Zealand Journal of Drugs and Therapy, 63-68.
94. Ward, J., Darke, S., Hall, W., & Mattick, R.P. (1992). Methadone maintenance and the human immunodeficiency virus: Current issues in treatment and research. British Journal of Addiction 87, 447-453.
95. Ward, J., W., Hall, W. & Mattick, R.P. (1998). Role of maintenance treatment in opioid dependence. Lancet 353, 221-226.
96. Ward, J., Mattick, R., Darke, S., & Hall, W. (1996). The effectiveness and safety of methadone maintenance (Letter). Addiction 91, 1727-1728.
97. Ward. J., Mattick, R.P., & Hall, W. (1991). The current role of methadone therapy for injecting drug users: An overview. Venereology 4, 109-111.
98. Ward, J., Mattick, R.P., & Hall, W. (1994). A review of the literature on the use of methadone maintenance treatment for opioid dependence. Drug and Alcohol Review 13, 327-336.
99. Ward, J., Mattick, R.P., Hall, W., & Darke, S. (1996). The effectiveness and safety of methadone maintenance. Addiction 91, 1717-1718.
100. Warner-Smith, M., Darke, S., & Day, C. (2002). Morbidity associated with non-fatal heroin overdose. Addiction 97, 963-968. (abstract available)
101. Warner-Smith, M., Darke, S., Lynskey, M.T., & Hall, W. (2001). Heroin overdose: Causes and consequences. Addiction 96, 1113-1125.
102. Warner-Smith, M., Lynskey, M., Hall, W., & Monteiro, M. (2001). Challenges attributable to illicit drug use. European Addiction Research 7, 104-116.
103. Warren, E., Viney, R., Shearer, J., Shanahan, M., Wodak, A., & Dolan, K. (2006). Value for money in drug treatment: Economic evaluation of prison methadone. Drug and Alcohol Dependence 84, 160-166.
104. Webb, G., Shakeshaft, A., Sanson-Fisher, R., & Havard, A. (2009). A systematic review of work-place interventions for alcohol-related problems. Addiction 104(3), 365-377.
105. Webster, P., Mattick, R.P., & Baillie, A.J. (1992). Characteristics of clients receiving treatments in Australian drug and alcohol agencies: A national census. Drug and Alcohol Review 11, 111-119.
106. Webster, I.W. & Richmond, R.L. (1989). Utilisation of ‘Smokescreen’ smoking-cessation programme (letter to the editor). Medical Journal of Australia 151, 487-488.
107. Wells, J. E., Degenhardt, L., Bohnert, K. M., Anthony, J. C., & Scott, K. M. f. t. N. Z. M. H. S. R. T. (2009). Geographical clustering of cannabis use: Results from the New Zealand Mental Health Survey 2003–2004. Drug and Alcohol Dependence 99(1-3), 209-316.
108. Westbrook, R.F. & Greeley, J. (1990). Some effects of the opioid antagonist, naloxone, upon the rat’s reactions to a heat stressor. Quarterly Journal of Experimental Psychology 42b, 1-40.
109. Westbrook, R.F. & Greeley, J.D. (1992). Conditioned tolerance to morphine: Compensatory hyperalgesia in the experimental group or conditioned hypoalgesia in the control group? Quarterly Journal of Experimental Psychology,45B.
110. Westbrook, R.F., Greeley, J.D., Nabke, C., Swinbourne, A., & Harvey, A.(1991). Effects of morphine and naloxone on rats’ reations to a heat stressor. Quarterly Journal of Experimental Psychology 43B, 323-346.
111. Westbrook, R.F., Greeley, J.D., Nabke, C., & Swinbourne, A. (1991). Aversive conditioning and analgesia in the rat: Effects of intensity of nociceptive stimulation, extinction, midazolam, morphine and naloxone. Journal of Experimental Psychology: Animal Behaviour Processes 17, 219-230.
112. White, B., Day, C., Degenhardt, L., Kinner, S., Fry, C., Bruno, R., & Johnston, J. (2006). Prevalence of injecting drug use and associated risk behaviour among regular injecting ecstasy users in Australia. Drug and Alcohol Dependence 83, 210-217.
113. White, B., Degenhardt, L., Breen, C., Bruno, R., Newman, J., & Proudfoot, P. (2006). Risks and benefits perceptions of party drug use. Addictive Behaviors 31, 137-142. (abstract available)
114. Wickes, W.A., Darke, S. & Ross, J. (2000). Clobazam maintenance among methadone maintenance patients with problematic benzodiazepine use: Five case studies. Drug and Alcohol Review 19, 401-405
115. Williamson, A., Darke, S., Ross, J., & Teesson, M. (2006). The effect of persistence of cocaine use on 12-month outcomes for the treatment of heroin dependence. Drug and Alcohol Dependence 81, 293 – 300.
116. Williamson, A., Darke, S., Ross, J., & Teesson, M. (2006). The association between cocaine use and short-term outcomes for the treatment of heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Review 25, 141-148.
117. Williamson, A., Darke, S., Ross, J., & Teesson, M. (2007). The effect of baseline cocaine use on treatment outcomes for heroin dependence over 24 months: Findings from the Australian Treatment Outcome Study. Journal of Substance Abuse Treatment, 33(3), 287-293.
118. Williamson, A., Darke, S., Ross, J., & Teesson, M. (2009). Changes and predictors of change in the physical health status of heroin users over 24 months. Addiction 104(3), 465-470.
119. Williamson, A., Feyer, A.M., Mattick, R.P., Friswell, R., & Finlay-Brown, S. (2001). Developing measures of fatigue using an alcohol comparison to validate the effects of fatigue on performance. Accident Analysis & Prevention 33, 313-326.
120. Winstock, A. R. (2008). Buprenorphine use by the smoking route in gaols in NSW. Drug and Alcohol Review, 27(4), 449-450.
121. Winstock, A. (2006). National Drugs Campaign--the GP's role in reducing illicit drug use. Australian family physician., 35(3), 121-123.
122. Winstock, A. R., Anderson, C. M., & Sheridan, J. (2006). National survey of HIV and hepatitis testing and vaccination services provided by drug and alcohol agencies in Australia. Medical Journal of Australia, 184(11), 560-562.
123. Winstock, A. R., & Lea, T. (2007). Safe storage of methadone takeaway doses - a survey of patient practice. Australian and New Zealand Journal of Public Health, 31(6), 526-528.
124. Winstock, A.R., Lea, T. & Ritter, A. (2007). The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia. Drug and Alcohol Review 26, 411-416.
125. Winstock, A. R., Lea, T., & Sheridan, J. (2008). Patients' help-seeking behaviours for health problems associated with methadone and buprenorphine treatment. Drug and Alcohol Review, 27(4), 393-397.
126. Winstock, A. R., Nittis, M., & Lea, T. (2009). Opioid dependent patients’ experiences of and attitudes towards having their injecting sites examined. International Journal of Drug Policy 20(1), 85-89.
127. Winstock, A. R., Nittis, M., Whitton, G., & Lea, T. (2007). Opioid dependent patients' experiences of and attitudes towards having their injecting sites examined. International Journal of Drug Policy.
128. Wodak, A. (1990). Alcohol and women’s health: Cause for concern? Healthright 9, 17-22.
129. Wodak, A. (1990). Heroin legalisation: Totem and taboo revisited. Modern Medicine 3, 76-95.
130. Wodak, A. (1990). Alcoholism – what can the GP do? Modern Medicine 33, 76-95.
131. Wodak, A. (1990). Put your question: How do I get through the denial used by alcoholics? Patient Management 19, 59.
132. Wodak, A. (1990). The connection between HIV infection in injecting drug users and drugs policy. International Journal on Drugs Policy 1, 22-23.
133. Wodak, A. (1990). The never-ending story. Drug and Alcohol Review 9, 346-350.
134. Wodak, A. (1991). Preventing HIV spread among injecting drug users. The Lancet 336, 482.
135. Wodak, A. (1991). Recent advances in alcohol and drug research. Australian Journal of Psychopharmacology 5, 17-19.
136. Wodak, A. (1991). A wider view of alcohol consumption in Australia. Medical Journal of Australia 154, 838-839.
137. Wodak, A. (1991). Why the war on drugs has failed. Medical Journal of Australia 155, 37-38.
138. Wodak, A. (1991). Helping a medical colleague with a drinking or drug problem. Modern Medicine 34, 22-23.
139. Wodak, A. (1991). I feel like an alcohol advertisement (Editorial). Australian Journal of Public Health 153, 170-171.
140. Wodak, A. (1992). Taming demons: The reduction of harm resulting from the use of illicit drugs. Australian and New Zealand Journal of Medicine 22, 204-208.
141. Wodak, A. (1992). The dismal science and our favourite drug. (Editorial). Medical Journal of Australia 156, 747-748.
142. Wodak, A. (1992). The epidemic that Australia does not have to have. Today’s Life Sciences 4, 26-30.
143. Wodak, A. (1992) She who pays the piper calls the tune. (Editorial). Drug and Alcohol Review 11, 107-109.
144. Wodak, A. (1992). Controlling HIV infection behind bars: Questions, strategies and obstacles. Current Issues in Criminal Justice, 4, 28-36.
145. Wodak, A. (1992). HIV Infection and injecting drug use in Australia: Responding to a crisis. Journal of Drug Issues 22, 549-562.
146. Wodak, A. (1993). HIV infection in drug and alcohol practice. Medical Journal of Australia 158, 266.
147. Wodak, A. (1993). Here’s to your Health? (Editorial). Australian & New Zealand Journal of Medicine 23, 242-243.
148. Wodak, A. (1993). To takes up arms against a sea of drugs. The Journal of Contemporary Health Law and Policy 9, 323-335.
149. Wodak, A. (1997). Hepatitis C: Waiting for the Grim Reaper. Medical Journal of Australia 166, 284-285.
150. Wodak, A. (1997). Needle exchange: Just do it! AIDS Targetted Information 11, R47-R49.
151. Wodak, A. (1997). Public health and politics – the demise of the ACT heroin trial (Editorial). Medical Journal of Australia 167, 348-349.
152. Wodak, A. (1997). Injecting nation: Achieving control of hepatitis C in Australia. Drug and Alcohol Review 16, 275- 284.
153. Wodak, A. (1998). Health, HIV, infection, human rights and injecting drug use. Health and Human Rights 2, 24-41.
154. Wodak, A. (1998). Heroin prescribing: Nothing to fear but fear itself? (Editorial). Medical Journal of Australia 168, 590-591.
155. Wodak, A. (1998). Aspects of care for the hepatitis C positive patient. Australian Family Physician 27, 787-790.
156. Wodak, A. (1999). Responding to the epidemic of drug overdose deaths. Current Therapeutics 40, 9-11.
157. Wodak, A. (1999). What is this thing called harm reduction? (Editorial). International Journal of Drug Policy 10, 169-171.
158. Wodak, A. (1999). Regulating cannabis comparative perspectives: Summary and conclusions (Editorial). International Journal of Drug Policy Special Issue 10, 277-280.
159. Wodak, A. (1999). Naltrexone for alcohol dependence. Commentary. Modern Medicine of Australia, November, 128-129.
160. Wodak, W. & Baume, P. (1999). The New South Wales Drug Summit. Medical Journal of Australia 171, 12-13.
161. Wodak, A., & Des Jarlais, D.C. (1993). Strategies for the prevention of HIV infection among and from injecting drug users. Bulletin on Narcotics 45, 47-60.
162. Wodak, A. & Dolan, K. (1994). A tale of three viruses. Today's Life Science 6, 60-64.
163. Wodak, A. & Dolan, K. (1994). Evidence of HIV transmission in an Australian Prison. [letter to the editor. (Reply)]. Medical Journal of Australia 161, 509.
164. Wodak, A. & Dolan, K. (1996). HIV prevention in the community: Injecting drug users. Medical Journal of Australia 165, 266-67.
165. Wodak, A., Dolan, K., Imrie, A., Gold, J., Wolk, J., Whyte, B., & Cooper, D. (1987). Antibodies to the human immunodeficiency virus in needles and syringes used by intravenous drug abusers. Medical Journal of Australia 147, 275-276.
166. Wodak, A., Fisher, R., & Crofts, N. (1993). HIV infection among injecting drug users in Asia: An evolving public health crises. AIDS Care 5, 315-322.
167. Wodak, A. & Hall, W. (2001). Buprenorphine: Better late than never. Medical Journal of Australia 175, 349-350.
168. Wodak, A., McArthur, T., & Carroll, T. (1990). Drug and AIDS education for Australian youth the get real project. Hygie International Journal of Health Education IX , 8-10.
169. Wodak, A., Hall, W., Mattick, R.P., & Saunders, J.B. (2001) Naltrexone treatment for opioid dependence: Past, present and future. Drug and Alcohol Review 20, 349-350.
170. Wodak, A. & Lurie, P. (1997). A tale of two countries: Attempts to control HIV among injecting drug users in Australia and the United States. Journal of Drug Issues 27, 117-134.
171. Wodak, A. & Monheit, B.M. (1990). Methadone. Medical Journal of Australia 153, 742.
172. Wodak, A. & Moss, A. (1990). HIV infection and intravenous drug users: From epidemiology to public health. AIDS 4 (suppl 1), S105-S109.
173. Wodak, A., Richmond, R.L., & Wilson, A. (1990). Thiamine in beer: Issues in fortification of alcoholic beverages. Medical Journal of Australia 152, 97-99.
174. Wodak, A., Strathdee, S., Friedman, S.R., & Byrne, J. (1998). The global response to the threat of HIV infection among and from drug users. AIDS Targetted Information 12, R41-R44.
175. Wolk, J., Wodak, A., Morlet, A., Guinan, J.J., & Gold, J. (1990). HIV-related risk-taking behaviour, knowledge and serostatus of intravenous drug users in Sydney. Medical Journal of Australia 152, 453-458.
176. Wolk, J., Wodak, A., Guinan, J., Macaskill, P., & Simpson, J.M. (1990). The effect of a needle and syringe exchange on a methadone maintenance unit. British Journal of Addiction 85, 1445-1450.
177. Wood, E., Shakeshaft, A., Gilmour, S., & Sanson-Fisher, R. (2006). A systematic review of school-based studies involving alcohol and the community. Australian and New Zealand Journal of Public Health 30, 541-549.
178. Wutzke, S.E., Conigrave, K.M., Kogler, B.E., Saunders, J.B., & Hall, W.D. (2000). Longitudinal research: Methods for maximising subject follow-up. Drug and Alcohol Review 19, 159-163.
179. Zador, D. Sunjic, S., & Darke, S. (1996). Heroin-related deaths in New South Wales, 1992: Toxicological findings and circumstances. Medical Journal of Australia 164, 204-207.